Christian-Albrechts-Universität zu Kiel

Institut für Psychologie

Master's thesis

Exploring Cognitive Performance and Resting State EEG in Individuals following SARS-CoV-2 Infection

Submitted by:

Janka Marlene Hauffe

Matrikelnummer: 1125742

Mail: jankamarlene@gmx.de

Supervisors:

Prof. Dr. Christian Kaernbach

Christian Neumann, M.Sc.

31. march 2025

Abstract

Many individuals experience persistent symptoms after SARS-CoV-2 infection, with cognitive difficulties (CD) and fatigue being among the most common. However, self-reported CD often does not align with objective cognitive measures, suggesting that CD may reflect psychological and health-related factors rather than actual cognitive impairment. This study investigated CD and its associated symptoms, including fatigue, depression, anxiety, and sleep deprivation, as well as resting-state neural activity in individuals post-SARS-CoV-2 infection. A hierarchical cluster analysis was used to define clusters based on objective cognitive performance. The results indicate that psychological factors such as fatigue, anxiety, and sleep disturbances significantly contribute to the perception of CD when objective cognitive impairment is absent. No significant differences in beta or delta power were found between or within clusters, suggesting that these frequency bands may be more closely related to psychological symptoms, or that the objective cognitive impairment was not severe enough to show measurable effects.

Zuammenfassung

Viele Menschen leiden nach einer SARS-CoV-2-Infektion unter langanhaltenden Symptomen, wobei (selbstberichtete) kognitive Einschränkungen und Fatigue zu den häufigsten gehören. Allerdings können die selbstberichteten kognitiven Einschränkungen häufig nicht durch objektive kognitive Tests bestätigt werden. Dies deutet darauf hin, dass selbstberichtete kognitive Einschränkungen eher durch psychologische und andere gesundheitsbezogene Faktoren widergespiegelt werden können als durch objektive kognitive Defizite. Diese Studie untersuchte kognitive Einschränkungen und die damit verbundenen Symptome wie Fatigue, Depression, Angst und Schlafstörungen sowie die neuronale Aktivität im Ruhezustand bei Personen nach einer SARS-CoV-2-Infektion im EEG. Es wurde eine hierarchische Clusteranalyse durchgeführt, um Cluster basierend auf der objektiven kognitiven Leistung zu definieren. Die Ergebnisse zeigen, dass psychologische Faktoren wie Fatigue, Angst und Schlafstörungen einen wesentlichen Einfluss auf die Wahrnehmung kognitiver Einschränkungen haben, auch wenn keine objektiven kognitiven Beeinträchtigungen vorliegen. Zwischen den Clustern wurden keine signifikanten Unterschiede in der Beta- oder Delta-Aktivität festgestellt, was darauf hindeuten könnte, dass diese Frequenzbänder eher mit psychischen Symptomen in Verbindung stehen oder dass die in dieser Studie gemessenen objektiven kognitiven Beeinträchtigungen nicht schwerwiegend genug waren, um messbare Effekte zu zeigen.

Table of Contents

Introduction

Moments of disorientation, trouble concentrating, or forgetting simple tasks are common phenomena that most people recognize. For many individuals recovering from COVID-19, however, this mental cloudiness is more than a fleeting inconvenience. It is a persistent reminder of their illness. These cognitive challenges, along with fatigue and other lingering symptoms, continue to affect their daily lives long after the infection has passed.

Cognition is the most complex function of the brain (Birle et al., 2020) and encompasses a range of mental processes, including the acquisition, storage, manipulation, selection, and retrieval of information (Cambridge Cognition, 2015; Liu et al., 2024), as well as core cognitive functions such as attention, perception, learning, memory, language, problem-solving, thinking, and reasoning (Eysenck & Brysbaert, 2018). These cognitive abilities are vital for decision-making and adapting to daily challenges (Eysenck & Brysbaert, 2018).

But what happens when these vital cognitive abilities begin to decline? Cognitive decline refers to varying degrees of damage to cognitive function resulting from a range of causes (Birle et al., 2020; Liu et al., 2024). The global prevalence of cognitive impairment in adults over 50 years old ranges from 5.1% to 41%, with a median prevalence of 19% (Pais, Ruano, Carvalho & Barros, 2020). The prevalence increases with age (Liu et al., 2024; Pais et al., 2020). Cognitive impairment can range from subjective cognitive decline to mild cognitive impairment and more severe forms, such as dementia.

Cognition can be assessed using various methods, each differing in their level of objectivity and sensitivity (Cambridge Cognition, 2015). Recognizing the importance of cognition underscores the profound effects that cognitive impairment can have on an individual's independence and quality of life.

This thesis investigates cognitive decline and its associated symptoms in individuals following SARS-CoV-2 infection. An overview of COVID-19 and its association with cognitive impairment in post-COVID-19 syndrome is first provided. The distinction between subjective cognitive decline and objective cognitive impairment is explained, followed by a discussion of the impact of neuropsychiatric symptoms on cognitive difficulties. Next, the role of electroencephalography (EEG) as a neurophysiological tool for assessing cognitive function is introduced. Following this, existing EEG research on subjective and objective cognitive impairment, as well as its application in post-COVID-19 syndrome, is reviewed. Finally, the specific aim of this thesis is introduced, which is to explore how differences in objective cognitive performance in individuals after SARS-CoV-2 infection relate to perceived cognitive functioning, associated neuropsychiatric symptoms, and EEG alterations.

Theoretical Background

As of September 2024, over 760 million confirmed cases of coronavirus disease 2019 (COVID-19) have been documented by the World Health Organization (WHO) globally, leading to approximately 6.9 million deaths (WHO, 2023). The actual numbers are likely to be much higher due to underreporting. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus (WHO, 2021). While most patients fully recover, some experience persistent symptoms such as fatigue, shortness of breath, cognitive dysfunction, and other symptoms that generally have an impact on everyday functioning (WHO, 2021). These remaining effects, referred to as Post-COVID-19 Condition or Syndrome (PCS), usually occur three months after the initial infection with the SARS-CoV-2 virus and last for at least two months with no other explanation. Approximately 10-20% of people infected with SARS-CoV-2 meet the criteria for PCS (WHO, 2021).

Cognitive Impairment in PCS

Cognitive impairment is one of the most frequent symptoms of PCS (Davids et al., 2021; WHO). It affects several cognitive domains, highlighting the diversity of cognitive deficits in PCS patients (Hasting et al., 2023; Widmann et al., 2023).

Cognitive Symptoms in PCS. Among the most frequently reported cognitive symptoms are lack of concentration, attention difficulties, and memory loss (Amin-Chowdhury et al., 2021, Buonsenso et al., 2021; Elkan et al., 2021; Ferrucci et al., 2021; Garrigues et al., 2020; Gonzalez-Hermosillo et al., 2021; Leth et al., 2021; Pilotto et al., 2021; Rauch et al., 2021; Soraas et al., 2021; Sykes et al., 2021; Woo et al., 2020). Patients also frequently report confusion, disorientation, mental slowness, trouble forming or finding words, increased time needed to perform tasks and difficulties in learning new skills (Amin-Chowdhury et al., 2021; Bland et al., 2024; Darley et al., 2021; Ferrucci et al., 2021; Fortini et al., 2021; Kwan et al., 2024; Morin et al., 2021; Woo et al., 2020). These symptoms are often collectively described by patients as "brain fog", a non-specific term used to express mental cloudiness, slowed thinking, and cognitive fatigue (Amin-Chowdhury et al., 2021; Bland et al., 2024; Fortini et al., 2021; Kwan et al., 2024; Widmann et al., 2023).

Neuropsychological assessments have identified executive functions, attention, verbal learning, processing speed, episodic memory, visuospatial processing, psychomotor coordination as the cognitive domains most frequently impaired (Becker et al., 2021; Damiano

et al., 2022; Delgado-Alonso et al., 2022; Ferrucci et al., 2021; García-Sánchez et al., 2022; Hasting et al., 2023; Mazza et al., 2021; Miskowiak et al. 2021).

Assessment of Cognitive Dysfunctioning in PCS. To evaluate these domains, various assessment tools have been employed in the literature, including, for example, the Orientation-Memory-Concentration test (OMC), Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT), Mini-Mental Status Examination (MMSE), Screen for Cognitive Impairment in Psychiatry (SCIP-D), and the Brief Repeatable Battery of Neuropsychological Tests (BRB-NT) (Leth et al., 2021; Mattioli et al., 2021; Morin et al., 2021; Pilotto et al., 2021; Miskowiak et al., 2021; Becker et al., 2021; García-Sánchez et al., 2022; Ferrucci et al., 2021; Frontera et al., 2022; Rass et al., 2021).

While some studies have found that PCS patients perform worse on these assessment tools (Clemente et al., 2023; Cecchetti et al., 2022 Ortelli et al., 2023; Rahimi et al., 2024), others did not find significant differences compared to healthy control (Appelt et al., 2022; Hasting et al., 2023). Importantly, even when group differences are found, patient scores often remain above the clinical cutoff for cognitive impairment (Hasting et al. 2023; Lynch et al., 2022). This shows, that despite the broad spectrum of neuropsychological assessment tools available, a considerable gap persists between subjectively reported cognitive difficulties (CD) and objectively assessed impairments.

Objective versus Subjective Impairment. Around 22% of individuals diagnosed with PCS experience COVID-19-related cognitive impairment, according to a meta-analysis by Ceban et al. (2022). This finding is based on data from 43 studies, 31 of which used subjective assessments and 12 that employed objective measures. Notably, studies using objective assessments of cognitive function reported significantly greater proportions of individuals with impairment (36%) compared to those relying on subjective modes of ascertainment, which identified 18% as cognitively impaired.

However, most studies have reported higher rates of cognitive impairment through subjective cognitive complaints than through objective test results (Schild, Scharfenberg, et al., 2023). Among 52 patients who self-reported cognitive impairment after SARS-CoV-2 infection, the MoCA confirmed impairment in only 25%, while extensive neurological assessment indicated impairments in 60% of these patients (Schild, Goereci, et al., 2023). Similarly, Gomzyakova, Palchikova, Tumova, Kasyanov and Sorokin (2022) found that objective CD, indicated by a MoCA score < 26, was detected in only 40 % of participants who

reported subjective CD. This raises questions about the sensitivity of the MoCA in detecting cognitive deficits, as it often yields results within the normal range (Hasting et al., 2023). Moreover, Schild, Scharfberg, Kirchner, et al. (2023) reported that 88% of patients reported persistent self-reported CD, with approximately a 40% discrepancy between the subjective reports and objective test results at both follow-up visits. In line with these findings, it was observed that there was no significant relation between objective and subjective measures of cognitive function, implying that self-reports of "brain fog" may not be reflected by objectively measured cognitive dysfunction (Bland et al., 2024; Brücket al., 2019). It remains unclear what these self-reported symptoms reflect.

Influence of Psychiatric and Health-related Symptoms on Cognitive Decline. "[…] subjective cognitive deficits in everyday situations are predicted by elevated anxiety and fatigue levels more than by objective cognitive performance" (Zamarian et al., 2004). In addition to cognitive impairment, PCS patients often experience a range of other symptoms, with fatigue being the most commonly reported alongside CD (Holdsworth et al., 2022; Premraj et al., 2022; WHO, 2021). Anxiety, depression, and sleep disturbances are also frequently observed (Almeria, Cejudo, Sotoca, Deus & Krupinski, 2020; Badinlou, Lundgren & Jansson-Fröjmark, 2022; Damiano et al., 2022; Deng et al., 2021; Holdsworth et al., 2022; Premraj et al., 2022). However, results on how these symptoms are associated with cognitive impairment are inconsistent (Almeria et al., 2020; Schild, Scharfenberg, et al., 2023). One study found that among ambulatory COVID-19 patients, objective cognitive test results were closely linked to anxiety, depression, fatigue, and pain, a pattern that was not observed in individuals hospitalized due to COVID-19 (Blackmon et al., 2022). In contrast, a study using the MoCA reported no significant correlation between MoCA scores and levels of depression and anxiety (Gomzyakova et al., 2022), which aligns with findings from a separate study that also found no association between objective cognitive impairment and depression, anxiety, sleep disturbance, or fatigue (Henneghan, Lewis, Gill & Kesler, 2022). However, both studies identified significant associations between these symptoms and subjective cognitive complaints (Gomzyakova et al., 2022; Henneghan et al., 2022). Similar associations have been reported in several other studies (Badinlou et al., 2022; Brück et al., 2019; Costas-Carrera et al., 2022; Hill et al., 2016). Conversely, objective cognitive function has been found to be more closely related to perceived stress (Bland et al., 2024).

Taken together, these findings support the assumption of Zamarian et al. (2024) that subjective cognitive deficits in PCS patients may be better explained by elevated anxiety and

fatigue, and further complemented by depression and sleep disturbance (Henneghan et al., 2022; Gomzyakova et al., 2022) rather than by objective cognitive performance.

Biological factors. Nonetheless, although individuals with self-reported CD perform within normal ranges on neuropsychological tests, they face an increased risk of developing mild cognitive impairment (MCI) and Alzheimer's disease (AD) (Li, Yue & Xiao, 2022; Numbers et al., 2023; Rivas-Fernández et al., 2023). Rivas-Fernández et al. (2023) suggest that subjective cognitive decline may manifest in brain structure or physiological changes before becoming evident in neuropsychological testing.

In fact, the persistent symptoms after COVID-19 infection may result from a combination of biological and psychological mechanisms (Premraj et al., 2022). For example, SARS-CoV-2 RNA may persist in brain tissue long-term, potentially contributing to progressive neuronal damage (Najjar et al., 2020; Singh, Chaubey, Chen & Suravajhala, 2020). Structural changes such as hippocampal atrophy, cortical thickening, and altered microstructural integrity have been associated with fatigue severity and cognitive deficits, particularly in attention and memory (Besteher et al., 2024; Díez-Cirarda et al., 2023; Heine et al., 2023). There are still many uncertainties about how and to what extent the virus impacts the brain. To better understand the nature and extent of these changes, neurophysiological methods such as electroencephalography (EEG) may offer valuable insights.

EEG as a Tool to assess cognitive impairment and related symptoms

EEG has been proven to be a valuable tool for assessing both subjective CD (Rossini, Rossi, Babiloni & Polich, 2007) and objective cognitive impairment such as MCI and AD (Babiloni et al., 2011; Dierks, Frölich, Ihl & Maurer, 1994; Jeong, 2004; Perez, Duque, Hidalgo & Salvador, Rossini et al., 2007, Yener, Güntekin & Başar, 2008).

EEG is a neurophysiological technique that records brain electrical activity via scalp electrodes (Babiloni et al., 2011; Babiloni et al., 2016), providing a direct, real-time view of human brain function in physiological and pathological conditions (Berger, 1929; Liu et al., 2024). The human brain consists of approximately 100 billion neurons, forming intricate synaptic networks that support cognitive function (Babiloni et al., 2016). As the brain ages, these synaptic networks weaken due to synaptic pruning, neuronal apoptosis, and the loss of cortico-cortical connections, leading to a decline in cognitive function (D'Amelio and Rossini, 2012). Pathological processes can accelerate this process of brain aging (Babiloni et al., 2016).

The value of EEG in studying cognitive impairment has been recognized for decades. Hans Berger introduced EEG in humans in 1924 and was the first to observe pathological EEG patterns in a verified AD patient (Berger, 1929; Jeong, 2004), laying the foundation for numerous studies on EEG in AD and other neurodegenerative disorders (Jeong, 2004). Several studies have found a strong correlation between the degree of disrupted or atypical brain wave patterns measured through EEG and cognitive impairment (Babiloni et al., 2016; Claus et al., 2020; Jelic et al., 2000; Kim et al., 2023). Babiloni et al. (2021) concluded, that EEG can serve as a supportive diagnostic tool for cognitive impairment, detecting brain dysfunction even before reaching pathological diagnostic criteria.

EEG studies have become increasingly relevant for investigating individuals with COVID-19 and PCS, as they reveal changes in brain neural activity. These changes correlate with fatigue, the most commonly reported symptom alongside cognitive decline, and cognitive deficits in these patients. (Antony & Haneef, 2020; Appelt et al., 2022; Cecchetti et al., 2022; Furlanis et al., 2023; Kopańska et al., 2022; Kubota, Gajera & Kuroda, 2021; Pasini et al., 2020; Pastor, Vega-Zelaya & Abad, 2020; Roberto, Espiritu, Fernandez & Gutierrez, 2020; Wojcik et al., 2023). Furlanis et al. (2023) found that two-thirds of the 20 participants presenting brain fog were characterized by unexpected abnormal EEG patterns. Ortelli et al. (2023) found that lower performance on cognitive tasks, particularly those assessing executive function, was associated with changes in brain activity in PCS patients.

EEG is a direct, non-invasive, safe, cost-effective, and portable method, making it a simple and convenient tool for assessing brain function (Babiloni et al., 2016; Babiloni et al., 2021; Biasiucci, Franceschiello & Murray, 2019; Meghdadi et al., 2021; Neo, Foti, Keehn & Kelleher, 2023; Rossini et al., 2019). Furthermore, EEG offers high temporal resolution (time resolution of ≤ 1 ms) (Biasiucci et al., 2019; Meghdadi et al., 2021; Rossini et al., 2004; Rossini et al., 2019).

Another advantage is its repeatability. EEG markers remain largely unaffected by meta-learning relative to task progression, allowing for repeated assessments throughout disease progression (Babiloni et al., 2016).

Resting-state EEG (rsEEG) has emerged as a valuable method for quantifying neurophysiological brain dysfunction (Babiloni et al., 2011; Babiloni et al., 2016; Perez et al., 2024). RsEEG captures spontaneous brain activity independently of cognitive tasks or stimuli (Babiloni et al., 2016; Babiloni et al., 2021; Mantini, Perrucci, Del Gratta, Romani & Corbetta, 2007; Perez et al., 2024), making it unaffected by factors such as fatigue, movement, anxiety, or meta-learning (Babiloni et al., 2016; Babiloni et al., 2021; Perez et al., 2024).

Frequency bands. Spectral power is one of the most commonly used parameters when analyzing EEG signals. EEG power refers to the squared amplitude of the signal and reflects the amount of energy within a specific frequency band. EEG signals are commonly categorized into five distinct frequency bands: Delta (1-4 Hz), theta (4-8 Hz), alpha (8-13 Hz), beta (13-30 Hz), and gamma (>30 Hz) (Babiloni et al., 2011; Babiloni et al., 2016). These frequency bands provide specific physiological insights into the brain's functional state during sleep and wake periods (Babiloni et al., 2011; Nunez et al., 1999). Attar (2022) defines the frequency bands as follows: Delta waves are typically absent during wakefulness in healthy adults and are primarily associated with deep sleep. Theta waves are associated with the transition between wakefulness and sleep. Alpha waves are characteristic of relaxed wakefulness. And beta waves are typically present when individuals are awake and mentally or physically active, or under psychological stress. However, there is no universal consensus on their exact frequency ranges, as definitions vary across studies. The current study will consider delta as 0.6-4 Hz and beta as 14-30 Hz.

During normal aging, eyes-closed rsEEG rhythms undergo gradual changes, including a shift in power distribution across frequency bands (Babiloni et al., 2011; Babiloni et al., 2016; Babiloni et al., 2006; Barry & De Blasio, 2017; Liu et al., 2024). However, in pathological aging, such as AD, these alterations become more pronounced and disruptive (Claus et al., 2000; Lejko et al., 2020; Liu et al., 2024).

A key feature of pathological aging is EEG slowing, which has been linked to cognitive impairment, where greater slowing is associated with worse impairment (D'Atri et al., 2021; Finnigan & Robertson, 2011; Lejko et al., 2020). This slowing is characterized by increased power in low-frequency band (delta, theta) and reduced power in high-frequency band (alpha, beta) (Farina et al., 2020; Lejko et al., 2020; Liu et al., 2024).

In AD, these EEG alterations are well-documented, with a consistent pattern of increased delta and theta power alongside reduced alpha and beta power compared to healthy older adults (Babiloni et al., 2011; Claus et al., 2000; D'Atri et al., 2021; Dringenberg, 2000; Elmståhl, Rosén & Gullberg, 1994; Hogan, Swanwick, Kaiser, Rowan & Lawlor, 2003; Jeong, 2004; Lejko et al., 2020; Musaeus et al., 2018; Özbek, Fide & Yener, 2021). However, findings in objective and self-reported CD remain less consistent (Froelich et al., 2021).

Investigating all frequency bands exceeds the scope of this work. Therefore, only beta and delta frequency bands will be further addressed. Sibilano et al. (2023) identified the delta band as the most effective in distinguishing subjective cognitive decline from mild cognitive impairment. Further, Farina et al. (2020) reported that the delta band provided the best

distinction between objective cognitive impairment and healthy controls. Several studies have also reported abnormalities in delta power in PCS patients (Furlani et al., 2022; Kopańska et al., 2022; Ortelli et al., 2023; Pastor et al., 2020), making it a relevant focus of investigation. The beta frequency band, on the other hand, is the least studied among the frequency bands (Güntekin, Emek-Savaş, Kurt, Yener, & Başar, 2013). Therefore, examining beta frequencies adds value by contributing to the number of EEG studies.

Delta findings. The literature presents conflicting findings relating delta activity to objective cognitive impairments. Several studies have observed increased delta power in individuals with objective cognitive impairment (Adler, Bramesfeld & Jajcevic, 1999; Babiloni et al., 2006; Babiloni et al., 2010; Farina et al., 2020; Jelic et al., 2000; Koenig et al., 2005; Moretti, Zanetti, Binetti & Frisoni, 2012), while others found no significant differences between MCI and healthy individuals (Froelich et al., 2021), and yet others reported a decrease in delta power during rsEEG (Kwak, 2006; Liddell et al., 2007). Liddell et al. (2007) observed a significant positive correlation between delta power and immediate memory recall in MCI, suggesting that delta power may be linked to memory decline and could serve as a sensitive indicator of prodromal cognitive decline. Similarly, Pastor et al. (2020) demonstrated a significant encephalopathic pattern in PCS patients characterized, among others, by an increase in generalized delta activity. However, in a study with 73 cognitively healthy older adults, relative delta frequency did not correlate with any cognitive measures (Finnigan & Robertson, 2011).

Ortelli et al. (2023) reported significant differences in the delta frequency band between PCS patients with self-reported CD and fatigue and healthy controls, with PCS patients displaying diminished activity compared to healthy controls. Lower delta power was associated with worse cognitive functioning. MoCA revealed significantly lower cognitive performance in PCS patients compared to HC. Interestingly, despite these differences, the global cognitive score in PCS patients remains within the normal range, indicating no clinically significant impairment. However, analyzing the MoCA subscores in each specific domain revealed significant deficits in executive functions, language, and memory in PCS patients compared to HC. These cognitive deficits were associated with brain activity changes in the frontal, parietal, and temporal brain regions at rest. Additionally, PCS patients showed significantly higher fatigue scores than HC, possibly reflecting shared neural mechanisms underlying both fatigue and cognitive dysfunction. Delta band activity in frontal regions has been shown to play a role in maintaining focused attention (Harmony, 2013). During mental tasks, increased delta power

is associated with the inhibition of sensory afferents that interfere with internal concentration (Harmony, 2013).

However, findings regarding delta power in PCS patients are not consistent. For instance, Kopańska et al. (2022) found a decrease in delta in the left hemisphere, similar to Ortelli et al. (2023), but also observed an increase in delta activity in the right hemisphere.

In a study by Furlani et al. (2022), EEG abnormalities were observed in 13 out of 20 patients who self-reported cognitive impairment following SARS-CoV-2 infection, with the abnormalities primarily located in the frontal brain regions. Among these, nine patients exhibited a delta-slowing pattern, while four showed epileptic discharges. There was no identifiable pattern to explain why some patients showed EEG abnormalities while others did not. No significant differences were found in age, education, or objective cognitive performance. The MoCA indicated objective impairment (score < 26) in 10 patients, six of whom had EEG abnormalities. The subscores in each specific domain of the MoCA also did not reveal any distinguishing pattern. Finally, no group differences were observed in fatigue levels. Interestingly, of the 20 patients with self-reported cognitive impairment, only two did not meet the threshold for clinically relevant fatigue (FFS ≥ 4.0). This highlights the association between self-reported CD and fatigue in patients following SARS-CoV-2 infection. And raises the question of whether subjectively reported cognitive impairment is primarily driven by fatigue and whether the observed slowing patterns in the data may reflect fatigue rather than actual cognitive impairment. Studies in which fatigue was induced found no changes in delta activity (Jap, Lal, Fischer & Bekiaris, 2009; Li et al., 2020).

Increased delta power has been reported in a longitudinal study, in which hospitalized patients with recent COVID-19 diagnosis and self-reported cognitive complaints underwent neuropsychological assessment and EEG within two months of infection (baseline) and ten months after infection (Cecchetti et al., 2022). At baseline, 53% of patients (n = 49) showed impairments in at least one cognitive domain on neuropsychological assessment, with executive functions being most affected and with overall worse performance compared to HC. Interestingly, 28% of patients reported psychiatric symptoms (10% depressive symptoms, 12% PTBS, and 6% both). Significantly greater delta power in bilateral frontal and central-temporal regions was found in patients compared to HC. At follow-up, a reduction in objective cognitive impairment was observed, with 36% of patients (n = 33) showing impairments in at least one cognitive domain, while delta frequency showed no significant changes over time. Notably, 33% of patients continued to report psychiatric symptoms (6% depressive, 18% PTSD, and 9% both). At follow-up, better performance on the TMT-BA was associated with higher baseline

left central-temporal delta power. Age, sex, education, and clinical and global cognition data did not differ between controls and patients.

To summarize, findings on delta power concerning cognitive impairment are inconsistent, with some studies reporting increased delta activity, while others show no significant differences or even decreases. In post-COVID-19 syndrome, changes in delta activity, particularly in the frontal and central-temporal regions, are associated with cognitive deficits, but the relationship between these findings and related symptoms, such as fatigue and depression, remains unclear.

Beta findings. Findings on beta power in objective cognitive impairment are also inconsistent. Several studies found no significant differences between objective cognitive impairment in beta power compared to healthy control (Babiloni et al., 2006; Froelich et al., 2021; Jelic et al., 1996). However, Jelic et al. (1996) noted a tendency toward higher beta values in frontal regions in individuals with objective memory disturbance, though this difference was not statistically significant. Conversely, other studies have reported a decrease in beta power (Babiloni et al., 2015; Jelic et al., 2020; Koenig et al., 2005), particularly in the temporal and occipital regions (Jelic et al., 2000).

While Ortelli et al. (2023) and Cecchetti et al. (2022) found no significant differences in beta frequency bands in PCS patients, Kopańska et al. (2020) reported increased higher beta frequency activity in both hemispheres and elevated lower beta frequency activity in the left hemisphere in PCS patients. In contrast, Gaber et al. (2024) observed decreased beta power in PCS patients. Further complexity in beta power findings was highlighted by Benis et al. (2024), who reported differential effects for low beta (13-19 Hz) and high beta (19-36 Hz) in a case report. The PCS patient with prominent apathy exhibited elevated high beta power but decreased low beta power compared to healthy controls. These conflicting findings suggest heterogeneous beta activity alterations in PCS, possibly influenced by individual differences in symptoms or underlying neurophysiological mechanisms.

In a review of rsEEG in psychiatric disorders, a dominant finding was an increase in absolute beta power in patients with depression (Newson & Thiagarajan, 2019). However, no significant difference was found in relative beta power. Another review suggests that increased beta power may be associated with high levels of anxiety in healthy participants, indicating abnormal hyperarousal and heightened brain alertness (Wang et al., 2025). Beta activity was found to significantly decrease in patients with induced fatigue (Jab et al., 2009). Further, sleep

deprivations seem to be related to higher relative and absolute beta (Corsi-Cebrera et al., 1992; Gorgoni et al., 2014), and delta power (Gennaro et al., 2007; Gorgoni et al., 2014).

In summary, the relationship between beta power and cognitive impairment remains unclear in the literature. Increased beta power has been observed in individuals with depression, anxiety, and sleep deprivation, while decreased beta activity has been associated with fatigue. However, these findings should be interpreted with caution, as the literature is limited.

Aim of study

As of yet, it has not been possible to differentiate between EEG patterns associated with cognitive impairment and those related to fatigue or psychiatric symptoms. However, EEG findings in PCS patients are mainly based on self-reported CD rather than objective measures of impairment. Therefore, this study aims to examine beta and delta power during resting state in groups defined solely by objective cognitive measures to provide a clearer understanding of the relationship between EEG patterns and cognitive functioning in patients with a history of SARS-CoV-2 infection.

Furthermore, this approach allows for a deeper subgroup analysis of beta and delta power and associated symptoms in relation to both self-reported CD and objectively observed impairments. Specifically, this examination explores whether differences in beta and delta power can be observed between groups where self-reported CD aligns with objectively measured CD but more importantly, it might provide insights into when and why these measures differ.

The study aims to explore the differences among groups that differ significantly in their objective cognitive performance levels following SARS-CoV-2 infection. This investigation is crucial given the widespread cognitive impairments reported in those individuals and their profound impact on everyday functioning and quality of life. Due to the inconsistent findings in EEG patterns in beta and delta power in patients with PCS, but also in patients with similar symptom patterns, there is a need for further investigation of this aspect. Specifically, the research will address the following research question: How do individuals with different cognitive performance levels differ in their self-perceived cognitive functioning after SARS-CoV-2 infection, their neuropsychiatric symptoms scores, and their resting state neural activity?

By examining the similarities and differences between objective cognitive assessments and self-reported CD, as well as the influence of related symptoms such as fatigue, depression, anxiety, and sleep deprivation, this study aims to provide insights into the complex relationship

between cognitive functioning and psychological health in individuals after SARS-CoV-2 infection.

Hypotheses

Following SARS-CoV-2 infection, two distinct groups of individuals will be identified based on objective cognitive assessments, with significant differences in performance levels between them. Based on this, the following hypotheses are proposed:

1. Individuals with objectively lower cognitive performance will report more frequent cognitive difficulties compared to those with higher objective performance.

2. Individuals who self-report cognitive difficulties but are not classified as low performers in objective cognitive assessments may have:
   a) Elevated fatigue levels
   b) Elevated anxiety levels
   c) Elevated depression levels

3. Concerning the delta frequency:
   a) A decrease in delta power is expected in patients with objectively lower cognitive performance compared to better performers.
   b) However, abnormal delta power may also be related to fatigue, suggesting that decreased delta power could be observed in patients with self-reported cognitive difficulties who do not exhibit lower objective cognitive performance.

4. Concerning the beta frequency:
   a) An increase in patients with objective lower performance compared to the better performers is expected.
   b) However, abnormal beta power may also be related to anxiety or depression, suggesting that increased beta power could be observed in patients with subjective cognitive impairment who do not exhibit lower objective cognitive performance.

Methods

The current data were collected as part of a larger research project EEG Post-Covid (EPOC), which investigates neurophysiological parameters identified from neuropsychological paradigms using a high-resolution stationary laboratory EEG to reflect cognitive impairments and fatigue. The primary goal of the EPOC study is to find EEG parameters that can serve as neurophysiological markers for progression- and therapy-evaluation concerning cognitive functions in PCS.

Participants

Participants for the EPOC study were recruited from COVIDOM, a population-based, prospective multi-center study to investigate PCS within the German National Pandemic Cohort Network (NAPKON). COVIDOM participants were recruited through public health authorities and were assessed between November 15, 2020, and September 19, 2021, at University Medical Center Schleswig-Holstein, Campus Kiel, and University Hospital Würzburg in Germany (Bahmer et al., 2022; Horn et al., 2021; Schons et al., 2022). Inclusion criteria for the COVIDOM study were: A polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection at least 6 months before the study visit, a primary residence in one of the three study regions, age $\geq$ 18 years at the time of recruitment (Berlin) or infection (Würzburg, Kiel). Participants with acute reinfection of SARS-CoV-2 at the time of the scheduled study visit were excluded (Horn et al., 2021).

In the EPOC study, a subset of individuals from Schleswig-Holstein who participated in COVIDOM was selected. Before participation in the EPOC, participants were asked wether they experienced ongoing cognitive difficulties as a long-term symptom of their SARS-CoV-2 infection. Based on their responses, they were assigned to either the "self-reported CD" group or the "no self-reported CD" group. No other factors were relevant for grouping.

As EPOC is still ongoing at the time of writing, the analysis was conducted based on a preliminary subset of 79 participants. Participants did not receive payment/financial compensation for their participation. Transportation and parking costs were reimbursed.

Ethics statement

The study was approved by the Ethics Committee of the medical faculty of the Christian-Albrechts-University of Kiel, Germany (record identification: D 446/23). In accordance with the Declaration of Helsinki, informed written consent was obtained from all participants.

Study design

The study was carried out at the University Medical Center Schleswig-Holstein (UKSH), Campus Kiel. Participants first filled out a questionnaire on demographic data (e.g. age, education) and psychological and neurological conditions (Appendix A), followed by neuropsychological testing to assess cognitive domains such as working memory, attention, preprocessing speed, cognitive flexibility, executive functions, and multisensory integration. The first test administered was the Trial Making Test (TMT). Following this, participants were seated comfortably in front of a 27-inch screen. The EEG cap was placed, and participants were

instructed to minimize movement. Electroencephalographic activity was recorded continuously while participants completed a series of additional neuropsychological tests, starting with the redundant target effect (RTE), followed by an auditory oddball paradigm, an n-back task, and lastly the psychomotor vigilance task (PVT). Finally, resting state activity was recorded for five minutes with eyes open and five minutes with eyes closed. During the eyes-open condition, participants were instructed to keep their gaze on a fixation cross displayed on the screen to reduce eye movement. An auditory signal at the end of the eyes-open recording cued participants to close their eyes. There was a short pause between each measurement during which participants received instructions for the upcoming task. The light was turned off during task execution. After completing the resting state measurement, the EEG cap was removed, and participants filled out three questionnaires assessing fatigue (FACIT-F), sleep quality (PSQI), depression (HADS-D), and anxiety (HADS-A). In all, the experiment took up to 3 hours.

Since this thesis focuses on behavioral data obtained from the TMT, n-back, and PVT, as well as rsEEG data, and data from the questionnaires, the RTE, and the oddball task will not be further explained. In addition, the MoCA score was measured in the previous COVIDOM study.

Objective cognitive assessment

MoCA. The Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005) is a widely used, validated screening tool originally designed to detect mild cognitive impairment (MCI) and dementia. It assesses several cognitive domains, including visuospatial skills, executive function, naming, memory, attention and concentration, language, abstraction, calculation, and orientation (Freitas, Simões, Alves & Santana, 2013; Hobson, 2015; Kang et al., 2018; Nasreddine et al., 2005). The MoCA has a total possible score of 30 points, with a score of $\geq$ 26 considered normal (Nasreddine et al., 2005). Cognitive performance on the MoCA is influenced by sociodemographic factors such as age and education (Kang et al., 2018; Larouche et al., 2016). To account for educational background the MoCA test manual specifies that one additional point is added for individuals with $\leq$ 12 years of formal education, allowing for a maximum score of 30 points (Nasreddine et al., 2005). Additionally, to address variations in performance related to age, normative data for the MoCA for individuals $\geq$ 65 years are available for precise interpretation of scores (Larouche et al., 2016).

TMT Part A and B. Originally, developed as part of the Army Individual Test Battery (AITB) in 1944, the Trail Making Test (TMT) was later integrated into the Halstead-Reitan

Battery (Reitan & Wolfson, 1985; Tombaugh, 2004). It is now one of the most popular and widely used neuropsychological assessments, included in most test batteries (Tombaugh, 2004). Its widespread use is supported by strong evidence of its validity (Arbuthnott & Frank, 2000; Sánchez-Cubillo et al., 2009). The TMT assesses cognitive processing speed and executive functioning (Lezak, 1995; Mitrushina et al., 2005; Sánchez-Cubillo et al., 2009; Strauss et al., 2016; Tombaugh, 2004), as well as visual search, and mental flexibility (Sánchez-Cubillo et al., 2009; Tombaugh, 2004).

The TMT consists of two parts: Part A (TMT-A), a number-connection task, and Part B (TMT-B), a number-letter alternation task. Both parts were administered according to the guidelines provided by Strauss et al. (2006).

In TMT-A, participants were instructed to connect consecutively numbered circles from 1 to 25 on an A4 page by drawing lines between them with a pencil, aiming to complete the task as quickly and accurately as possible. In TMT-B, the task becomes more complex (Gaudino, Geisler & Squires, 1995). Participants were instructed to draw lines alternating between numbered circles from 1 to 13 and lettered circles from A to L in sequential order (e.g. 1 to A, to 2, to B, etc.) on an A4 page. The aim, again, was to complete the task as quickly and accurately as possible.

The administration of the TMT began with TMT-A, followed by TMT-B. For each part, participants were first given an example to familiarize themselves with the task. After completing the example, they proceeded to the actual test. If participants made a mistake, the experimenter immediately pointed it out, and the participant was required to correct it before continuing. The experimenter timed each part, with the time of completion for each part representing its direct score. In addition to the direct scores, the difference between TMT-B and TMT-A (TMT-B – TMT-A) was calculated.

N-Back task. The n-back task (Kirchner, 1958) has become a widely used tool in neuroscience for assessing working memory (Jaeggi, Buschkuehl, Perrig & Meier, 2010; Pelegrina et al., 2015). N-back tasks are continuous-recognition measures, that present sequences of stimuli (Kane, Conway, Miura & Colflesh, 2007). In these tasks, participants must determine whether a given stimulus matches one that was presented in "n" trials before. The reliability of the n-back task varies across studies, with more complex levels (e.g., 2-back, 3-back) generally yielding higher reliability coefficients (Jaeggi et al., 2010; Pelegrina et al., 2015).

In this study, participants completed two blocks of the n-back task: A 1-back task followed by a 2-back task, with a pause between blocks during which the instructor provided additional instructions before participants proceeded to the second block. The task was programmed in PsychoPy and presented on a 27-inch computer screen.

In both conditions, participants were shown a series of 60 linguistic stimuli, consisting of 16 different consonants (**B, C, D, F, G, H, J, K, M, Q, R, S, T, V, X, Z**) presented individually in the center of the screen. Each block contained 20 target trials and 40 non-target trials. A trial began with a 250 ms fixation period (a red dot was shown on the screen, for the participant to fixate), followed by a 150 ms black screen. The stimulus letter then appeared for 500 ms, succeeded by a variable inter-trial interval of 180 to 220 ms (black screen). Total trial duration ranged from 1080 to 1120 ms (Figure 1).


Figure 1. The n-back task

For the 1-back task, participants were instructed to press the spacebar when the current letter matched the previous one. For example, in the sequence "B, C, C, D," participants were supposed to respond to the second "C" as it matches the previous letter (Figure 1, A). In the 2-back task, they were instructed to press the spacebar when the current letter matched the letter presented two trials prior. For instance, in the sequence "B, B, D, F, D," participants should press the spacebar when the second "D" occurred, as it matches the letter presented two trials before (Figure 1, B). The response window was limited to the 500 ms stimulus presentation period. Reaction time, hits, misses, and false alarms were recorded. In total, the experiment took around five minutes.

PVT. The Psychomotor Vigilance Task (PVT) is a widely used reaction time task developed in 1985 to assess sustained attention, particularly in contexts involving fatigue and sleep deprivation (Drummond et al., 2005). It has been shown to be sensitive to sleepiness in clinical and experimental settings (Molina, Sanabria, Jung & Correa, 2019).

The key feature of the PVT is its monotonous and unpredictable target presentation which makes participants highly prone to lapses of attention. This unpredictability minimizes learning effects, ensuring that performance remains largely independent of prior abilities and experience (Basner & Dinges, 2011). Reaction time measured by the PVT has been linked to cognitive function in both healthy subjects and patients, supporting its validity as an assessment tool (Jakobsen, Sorensen, Rask, Jensen & Kondrup, 2011).

This study employed a 5-minute version of the PVT, which has been established as a valid alternative to the traditional 10-minute PVT-192 (Lamond et al., 2008).

The dynamic stimulus appeared as a red number, counting up in milliseconds, representing the participant's reaction time. Participants were instructed to respond immediately, when the stimulus occurred, by pressing the spacebar. Between trials, a white fixation cross was displayed on a black screen for a variable interval ranging from 2 to 10 seconds. Participants were required to maintain their gaze on this fixation cross. Each trial concluded when a response was made. Following each response, the participant's reaction time was displayed on the screen for 500 ms as feedback before the next trial began (Figure 2).

After receiving instructions, participants underwent a training block of 8 trials to familiarize themselves with the task. Following the training, participants proceeded to the main experiment, which consisted of 50 stimulus presentations.

Figure 2. The Psychomotor Vigilance Task (PVT)

Questionnaires

   PSQI. The Pittsburgh Sleep Quality Index (PSQI), developed by Buysse, Reynolds, Monk, Berman, and Kupfer in 1989 is a self-rated questionnaire that assesses sleep quality and disturbance over the past month. The PSQI is the most commonly used sleep health assessment tool in both clinical and research settings (Manzar et al., 2016). Its reliability and validity have been consistently demonstrated in multiple studies (Carpenter & Andrykowski, 1998; Manzar et al., 2018; Mollayeva et al., 2016). The questionnaire consists of 24 items in total, 19 of which are self-reported by the patient and 5 of which require input from a room or bed partner. Only the 19 self-reported items are used for the quantitative evaluation of sleep quality, as perceived by the patient (Buysse et al., 1989; Manzar et al., 2018). The response formats across the items vary, including the recording of usual bed and wake times, number of hours slept, minutes taken to fall asleep, as well as forced-choice Likert-type responses (Buysse et al., 1989). The items are categorized into seven components, which are sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction, for each component given a score. Together, these component scores generate a global sleep quality score ranging from 0 to 21, with scores >5 indicating poor sleep quality (Buysse et al., 1989; Hinz et al., 2017).

   HADS. The self-assessment Hospital Anxiety and Depression Scale (HADS) was originally developed by Zigmond & Snaith in 1983 to identify the presence of anxiety and

depression states among patients in non-psychiatric hospital clinics. HADS is an extensively used, reliable, and valid instrument to measure anxiety and depression, not only in psychiatric, and clinical patients (Herrmann, 1997) but in general populations (Bjelland, Dahl, Haug & Neckelmann, 2002; Herrero et al., 2003; Spinhoven et al., 1997). The questionnaire assesses anxiety and depression symptoms during the past week, excluding symptoms also related to physical disorders, e.g., headache, dizziness, or insomnia (Bjelland et al., 2002; Hinz & Braehler, 2011; Zigmond & Snaith, 1983). The scale consists of 14 items, divided into a 7-item anxiety (HADS-A), and a 7-item depression subscale (HADS-D). Both subscales are rated on a four-point Likert scale, giving subscale scores ranging from 0 to 21 (Zigmond & Snaith, 1983). There is no universally accepted cut-off score for the HADS (Herrero et al., 2003; Spinhoven et al., 1997). In this study, the cut-off point was set to eight, indicating caseness anxiety and depression for scores ≥8, following the recommendations by Zigmond and Snaith (1983), as well as Bjelland et al. (2002) and Herrero et al. (2003).

FACIT-F. The 13-item Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) was used to assess self-reported fatigue and its impact on daily activities and functions (Cella, Lai, Chang, Peterman & Slavin, 2002; Yellen et al., 1997) during the last 7 days. While it was originally developed for cancer-related fatigue (Cella et al., 2002; Yellen et al., 1997), it has been shown, that the FACIT-F is a reliable and valid measure of fatigue across various health conditions (Cella et al., 2002), making it a widely used tool for both clinical practice and research (Cella et al., 2022; Butt et al., 2013; Montan, Löwe, Cella, Mehnert & Hinz, 2018; Tinsley, Macklin, Korzenik & Sands, 2011). This questionnaire utilizes a five-point Likert scale, with total scores ranging from 0 (severe fatigue) to 52 (no fatigue). Based on general population data, scores ≤30 indicate clinically significant fatigue (Piper & Cella, 2010).

Data Analysis

All codes described in the data analysis part can be found in this GitHub repository: https://github.com/JankaMarlene/masters_thesis.

Cluster Analysis. To classify individuals based on objective cognitive assessment, a cluster analysis was conducted. Cluster analysis is an exploratory statistical method that organizes objects, data points, or observations into homogeneous groups, known as clusters, based on similarities (Ketchen & Shook, 1996). The objective is to maximize intragroup homogeneity while ensuring high intergroup heterogeneity (Bacher, Pöge & Wenzig, 2010; Backhaus,

Erichson, Gensler, Weiber & Weiber, 2011). Cluster analysis does not follow a straightforward, single-step procedure but rather involves a multi-stage process, with each step depending on the outcome of the previous one (Bacher & Wenzig, 2010). Consequently, the analysis and interpretation of results may require revisiting certain steps, particularly when the initial outcomes do not allow for a meaningful interpretation (Backhaus et al., 2011). The goal was to identify the best possible solution for the dataset. The cluster analysis was conducted in R (version 2024.4.2.764) within Rstudio (Posit Team, 2024).

Ward's method was selected for clustering, as it is widely used in practice and known for its effectiveness in identifying distinct clusters (Backhaus et al., 2011) with squared Euclidean distance as a distance matrix. It is considered a reliable algorithm, provided that the variables are on a metric scale, are uncorrelated, and do not contain outliers (Wentura & Pospeschill, 2015).

Before the initial clustering, data were preprocessed to meet the methodological requirements of the algorithm. The MoCA variable was converted to a binary variable, with scores ≤25 indicating cognitive impairment, as the test is designed to screen for impairment without assessing severity (Nasreddine et al., 2005) For the n-back task, missing values were assigned if a participant reported not understanding the task. To ensure complete cases for analysis, rows with missing values in relevant cognitive variables were removed.

Addressing outliers was essential, as they can significantly impact the result by distorting the clustering process, obscuring underlying patterns, and introducing bias (Backhaus et al., 2011; Wentura & Pospeschill, 2015). To mitigate these effects, winsorizing was applied, to replace outliers by capping extreme values beyond 1.5 times the interquartile range (IQR) for the relevant cognitive variables ($Q1 \pm 1.5 \cdot IQR$). In total, four outliers were detected and winsorized for PVT reaction time, two for TMT-A time, and four for TMT-B time.

Where appropriate, age adjustment of neurocognitive data was performed in a way that best reflected the sample distribution (Table B-1) under the assumption that cognitive performance declines with increasing age (Tombaught, 2004; Strauss, Sherman & Spreen, 2006). Subsequently, data were standardized (z-scores) allowing for comparison between measures and ensuring that each variable contributed equally to the distance measure. Exploratively, different combinations of variables were tested to identify those that best distinguish between levels of cognitive performance. The number of clusters was chosen based on visual inspection of the dendrogram.

EEG Recording and Analysis. For each participant, 5 minutes of resting state with eyes open and 5 minutes of resting state with eyes closed were recorded using high-density EEG. Since the eyes-closed condition represents a simple, standardized procedure (Babiloni et al., 2016), it is the most commonly used (Babiloni et al., 2022) and will therefore be analyzed in this study to ensure comparability. EEG signals were recorded using a 128-channel EEG cap (128Ch Standard Brain Cap for actiCHamp Plus, Easycap GmbH, Wörthsee, Germany) with electrodes positioned in an equidistant layout, connected to an actiCHamp Plus Amplifier (Brain Products GmbH, Gilching, Germany).

The sampling rate was 1000 Hz with an amplitude resolution of 0.1 µV. Electrolyte gel was applied to improve conductivity between skin and electrodes, ensuring impedances remained below 20 kΩ. Eye movements and changes in the resting potential of the retina (EOG activity) were monitored using two EOG electrodes placed below each eye, with impedances tried to maintain below 20 kΩ. In addition, a ground electrode was positioned on the forehead, and a reference electrode was positioned on the tip of the nose. Impedances for both the reference and ground electrode were tried to be kept below 5 kΩ.

Preprocessing. Data preprocessing was performed using the FieldTrip toolbox (Fieldtrip-20240504; Oostenveld, Fries, Maris & Schoffelen, 2011) and the EEGLab toolbox (v2024.0; Delorme & Makeig, 2004) in Matlab (v24.1.0.2578822 (R2024a) Mathworks Inc., 2024, MathWorks® https://de.mathworks.com) on Windows.

Filtering and Resampling. A finite impulse response (FIR) windowed-sinc (firws) filter, designed with a hamming windowed sinc function, was used for both high-pass and low-pass filtering of the continuous data. For high-pass filtering, a cut-off frequency of 0.1 Hz was applied to eliminate slow drift and offset effects (Keil et al., 2013). This cut-off was based on the findings of Delorme (2023) and Winkler, Debener, Müller, and Tangermann (2015), where filtering at 0.1 Hz or higher significantly improved data quality compared to no filtering.

Before applying low-pass filtering, the data was downsampled from 1000 Hz to 250 Hz, to reduce computational load while preserving sufficient temporal resolution for subsequent analysis. A cut-off frequency of 45 Hz was then used to eliminate high-frequency noise and mitigate potential 50 Hz line noise (Delorme, 2023). Finally, the data underwent re-referencing using the Common Average Reference (CAR) technique to remove the influence of the reference and improve signal quality (Ludwig et al., 2009). As the name implies, an average of

the recordings from all electrode sites was computed and used as the reference (Ludwig et al., 2009; Offner, 1950).

Artifact removal. After the initial filtering and resampling, artifacts were detected and removed. First, large artifacts were removed from the data. Channels with flat lines for more than 5 seconds were removed. This ensured the exclusion of "dead" or disconnected channels, thereby improving data quality (Pernet et al., 2021). Channels were further excluded if their signal could not be predicted from a randomly selected subset of the remaining channels for at least 85% of the recording time, to remove those that were highly dissimilar from the rest of the channels (Gil Ávila et al., 2023; Pernet et al., 2021). The Euclidean distance metric was used to calculate the similarity between channels. Data segments with abnormally high amplitude bursts, exceeding 100 *SD* compared to neighboring segments, were eliminated, as such extreme bursts are considered unlikely to reflect brain signals (Chang et al., 2018). The default BurstCriterion is set to 20, but it may be adjusted if the default setting results in rejecting too many data segments. Some scientists recommend setting the threshold to 100 (EEGLAB, "Automated Pipeline Tutorial", 2024), which aligns with the optimal cut-off range of 10 to 100 suggested by Chang et al. (2018). Therefore, a mild threshold of 100 was chosen here, as it still effectively removes large-amplitude artifacts while retaining valuable data (Chang et al., 2018). Time windows where more than 40% of the channels were marked as noisy were removed, to ensure the quality of the remaining data. A more lenient threshold of 0.4 was chosen over the default of 0.25 to retain more data (even if it is potentially noisier). Again the data was re-referenced to the average reference (CAR) (Gil Ávila et al., 2023).

Secondly, Independent Component Analysis (ICA) (Bell and Sejnowski, 1995; Hyvärinen, 2013, Jung et al., 2000; Lee et al., 1999; Palmer et al., 2008) was performed on the data, to detect and reject further artifacts, such as eye or muscle movements (Makeig et al., 1995). ICA with the runica algorithm was employed with the extended InfoMax method. To avoid rank deficiency, the number of components was set to one less than the total number of channels (Kim, Luo, Chu, Cannard, Hoffman & Miyakoshi, 2023). This approach decomposes the EEG signal into independent components, potentially separating artifacts from neural activity. Due to the non-deterministic nature of the ICA algorithm, its results vary across repetitions (Gil Ávila et al., 2023).

Automatic component rejection was implemented using ICALabel (Pion-Tonachini, Kreutz-Delgado & Makeig, 2019), as automatic artifact rejection is preferred over manual one to ensure standardization (Miljevic et al., 2022). Artifactual components are automatically

classified by the ICLabel classifier (Pion-Tonachini et al., 2019). Thresholds were set at probabilities of 0.8 (80%) for muscle-related components (Pernet et al., 2021) and 0.5 (50%) for eye-related components. Components exceeding these thresholds were flagged and automatically removed. The two EOG channels (31 and 32) were removed from the dataset. The cleaned dataset was then checked for consistency.

Thirdly and finally, an additional artifacts removal step was implemented to address any remaining problematic channels. This process involved a statistical approach to identify outlier channels based on their signal characteristics. The standard deviation and mean were calculated for each channel across all time points. Then, overall mean values for these standard deviations and means were computed across all channels. Thresholds were established at 2.5 standard deviations above and below the overall mean, creating an acceptable range for channel activity. Channels with standard deviations falling outside this range were removed. This step ensures that channels with unusually high or low variability, which might represent persistent artifacts or malfunctioning electrodes, are excluded from subsequent analyses.

Channels removed in the previous step were interpolated with the default spherical splines method (Perrin, Pernier, Bertrand & Echallier, 1989), ensuring a consistent number of channels across participants (Gil Ávila et al., 2023). Data was then segmented into epochs, to achieve high resolution, while maintaining an adequate trial count (Bonello, Garg, Garg & Audu, 2018).

Power Analysis. Preprocessed EEG data were converted from EEGLAB format to FieldTrip format. Spectral parameterization was performed using SpecParam (formerly FOOOF, Fitting Oscillations & One Over F; Donoghue et al., 2020), which is implemented in the Brainstorm Toolbox (Tadel et al., 2011) and available in FieldTrip. This approach separates the periodic and aperiodic components of the power spectrum.

Spectral analysis of relative power across the 128 scalp electrodes was conducted using FieldTrips's multitaper spectral estimation with Hanning taper, analyzing frequencies between 0.3 and 30 Hz with a frequency resolution of 0.2 Hz. The fooof output was set to a fixed aperiodic mode. Delta power was defined as 0.6-4 Hz and beta power as 14-30 Hz. The summed power across all frequencies within each band was used to compute the relative power per channel.

Once the relative power per channel was computed, further analysis was performed in R (version 2024.4.2.764) within Rstudio (Posit Team, 2024). To identify and remove extreme values, an initial outlier detection was performed. For each participant, channels exceeding ± 3

SD from the mean relative power were excluded. This process was applied separately for delta power and beta power.

Statistical Analysis. The resulting clusters were compared across cognitive measures, demographic variables, questionnaire scores, and their relative beta and delta power in rsEEG to identify emerging patterns. Particular attention was given to how the objective results of the cluster analysis aligned with or differed from self-reported CD, how associated variables help explain these findings, and how rsEEG beta and delta power are related to this.

To address this, comparisons were conducted not only across clusters but also between all relevant subgroups. To ensure the validity of statistical testing, assumptions for t-tests and ANOVA were first examined. The Shapiro-Wilk test was used to assess normality, and Levene's test was applied to evaluate the homogeneity of variances. When these assumptions were violated, the non-parametric Wilcoxon test was used. For comparisons involving more than two groups, the Kruskal-Wallis test was used to determine whether significant group differences existed in the examined variable. If significance was indicated, pairwise Wilcoxon rank-sum tests with Bonferroni correction were performed as a post-hoc analysis. To test correlations, Spearman's rank correlation was calculated.

Results

Hierarchical clustering

To investigate groups that differ as strongly as possible in their objective cognitive performance, a hierarchical cluster analysis was conducted using Ward's method with Euclidean distance.

From the initial sample, nine participants were excluded due to missing values in at least one of the cognitive variables, TMT, n-back, or PVT. This resulted in a final sample of 70 participants for the cluster analysis. The final clustering was based on completion times in TMT-A and TMT-B, as well as reaction time in the PVT. Since the TMT difference score (TMT-diff) is derived from TMT-B and TMT-A, it was not considered a clustering variable to avoid redundancy and thereby unequal weighting of the variables.

The inclusion of the n-back task as a clustering variable resulted in poorer cognitive differentiation between clusters compared to when it was excluded. Participants generally performed poorly on the n-back task, particularly in the 2-back condition ($M = 13.5$ missed targets, range = 3–20), resulting in low variability and limited discriminative power. Consequently, n-back scores were not used as cluster variables. Visual inspection of the

dendrogram revealed that a reasonable number of resulting clusters could be either two (Figure C-1) or four (Figure C-2). Both the two-cluster and four-cluster solutions were examined in terms of their differences.

Two-cluster solution. The identified cluster 1 (C1) comprised 41 participants, of whom 33 reported subjective CD. Cluster 2 (C2) comprised 29 participants, with 10 reporting subjective CD (Table 1). A comparison between the two clusters was conducted using the nonparametric Wilcoxon test, as the assumptions of normal distribution and homogeneity of variance were not met for most variables. All results are listed in Table 1. The participants of C2 completed the TMT and reacted in PVT significantly faster than participants in C1. Missed targets in the n-back task were significantly more frequent in C1 compared to C2. No significant differences were found between clusters in age, level of education, fatigue score, quality of sleep, anxiety, and depression. No abnormal values were observed in HADS or FACIT-F. However, PSQI scores indicated poor sleep quality in both clusters (C1: $M = 7.4$, $SD = 4.3$; C2: $M = 6.2$, $SD = 3.7$).

To allow for a more in-depth analysis, the subgroups *no self-reported CD (C1)*, *self-reported CD (C1)*, *no self-reported CD (C2)* and *self-reported CD (C2)* were compared (Table C-2).

In addition to the observed group differences in cognitive variables, the Kruskal-Wallis test revealed significant group differences across all questionnaire scores (Table C-3). Dunn's post hoc tests indicated significant differences between the *no self-reported CD (CD)* and *self-reported CD (C2)* groups in PSQI, FACIT-F, and HADS-A scores (Figure 3). The *self-reported CD (C2)* group showed the most severe scores across all questionnaire measures compared to the other three subgroups. It was the only subgroup exhibiting clinically significant fatigue (FACIT-F: $M = 27.7$, $SD = 11.1$) and elevated levels of anxiety (HADS-A: $M = 8.00$, $SD = 3.3$). In contrast, the *no self-reported CD (C2)* group showed the least severe scores relative to the other three subgroups.

Table 1

Two-Cluster Solution: Cluster Information and Comparison

	Cluster 1	Cluster 2	*p*
Socio-demographic variable			
n	41	29	-
Reported CD	33	10	-
No reported CD	8	19	-
Sex [F/M]	27/14	14/15	-
Age [years]	50.6 ± 14.8	47.9 ± 12.1	.316
Education [years]	14.9 ± 2.8	15.8 ± 3.4	.412
Cognitive variable			
PVT [s]	.357 ± .07	.29 ± .02	4.38e-09***
TMT-A [s]	30.0 ± 8.0	19.5 ± 4.0	1.25e-08***
TMT-B [s]	62.8 ± 25.2	42.0 ± 10.5	4.44e-05***
TMT-diff [s]	32.8 ± 22.1	23.5 ± 9.5	.113
1-back [miss]	11.3 ± 5.2	5.8 ± 3.9	1.50e-05***
2-back [miss]	15.6 ± 3.0	10.5 ± 4.0	9.69e-07***
MoCA < 26	9	2	-
Questionnaires			
FACIT-F[a]	33.2 ± 12.4	37.2 ± 11.4	.182
HADS-Anxiety[b]	6.7 ± 3.8	5.2 ± 3.7	.190
HADS-Depression[b]	5.7 ± 4.6	4.4 ± 4.3	.103
PSQI[c]	**7.9 ± 4.3**	**6.2 ± 3.7**	.147

Note. PVT: Psychomotor Vigilance Task, TMT: Trail Making Test, MoCA: Montreal Cognitive Assessment, FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue Scale, HADS: Hospital Anxiety and Depression Scale, PSQI: Pittsburgh Sleep Quality Index

Values denote mean ± standard deviation

P values refer to the Wilcoxon rank-sum test ($p < .05$)

[a] scores < 31 indicate clinically significant fatigue

[b] scores > 7 indicate caseness

[c] scores > 5 indicate poor sleep quality

Figure 3. Two-Cluster Solution: Comparison of the four subgroups in questionnaire scores. Significant Bonferroni-adjusted p-values are shown in the plot. Dunn's test was used for pairwise group comparisons. FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue Scale, HADS: Hospital Anxiety and Depression Scale, PSQI: Pittsburgh Sleep Quality Index.

Four-cluster solution. C2 remained unchanged from the two-cluster solution, while C1 was divided into three new clusters (Figure C-2). The updated clustering resulted in C1 comprising 17 participants (13 with self-reported CD), C3 comprising 16 (13 with self-reported CD), and C4 comprising 13 (6 with self-reported CD) participants (Table 2).

Table 2

Four-Cluster Solution: Cluster Information

	Cluster 1	Cluster 2	Cluster 3	Cluster 4
Socio-demographic variable				
n	17	29	16	8
Reported CD	13	10	13	7
No reported CD	4	19	3	1
Sex [F/M]	13/4	14/15	9/7	5/3
Age [years]	47.5 ± 16.0	47.9 ± 12.1	52.4 ± 13.4	53.4 ± 15.0
Education [years]	15.2 ± 2.7	15.8 ± 3.4	14.5 ± 2.7	15.1 ± 3.4
Cognitive variable				
PVT [s]	.38 ± .08	.29 ± .02	.31 ± .02	.42 ± .05
TMT-A [s]	25.9 ± 6.5	19.5 ± 4.0	30.9 ± 7.8	36.7 ± 6.7
TMT-B [s]	46.5 ± 9.7	42.0 ± 10.5	67.2 ± 19.4	88.4 ± 34.3
TMT-diff [s]	20.6 ± 6.4	23.5 ± 9.5	36.3 ± 21.3	51.7 ± 30.3
1-back [miss]	11.1 ± 4.0	5.8 ± 3.9	9.8 ± 5.6	14.9 ± 5.6
2-back [miss]	14.5 ± 3.0	10.5 ± 4.0	16.1 ± 2.9	17.3 ± 2.6
MoCA < 26	1	2	3	5
Questionnaires				
FACIT-F[a]	32.2 ± 13.7	37.2 ± 11.4	36.1 ± 11.7	**28.9 ± 10.8**
HADS-Anxiety[b]	6.9 ± 4.1	5.2 ± 3.7	6.1 ± 3.6	7.1 ± 3.6
HADS-Depression[b]	5.5 ± 4.7	4.4 ± 4.3	6.3 ± 5.1	5.0 ± 3.6
PSQI[c]	**8.4 ± 4.6**	**6.2 ± 3.7**	**7.1 ± 4.5**	**8.2 ± 2.8**

Note. PVT: Psychomotor Vigilance Task, TMT: Trail Making Test, MoCA: Montreal Cognitive Assessment, FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue Scale, HADS: Hospital Anxiety and Depression Scale, PSQI: Pittsburgh Sleep Quality Index

Values denote mean ± standard deviation

[a] scores < 31 indicate clinically significant fatigue

[b] scores > 7 indicate caseness

[c] scores > 5 indicate poor sleep quality

The data did not meet the assumptions of normality and homogeneity of variance. Therefore, the Kruskal-Wallis test was used to identify overall differences between clusters, and Dunn's post hoc tests were applied to further examine these differences (Table B-4).

Participants in C2 showed the best overall cognitive performance, performing significantly better than all other clusters across all cognitive tests. In contrast, participants in C4 demonstrated the lowest performance across all cognitive measures, with significantly lower cognitive performance in all tests compared to participants in C2. Participants in C1 performance better on TMT-A and significantly better on TMT-B, but performed significantly lower in PVT compared to participants from C3 (Figure 4).


Figure 4. Four-Cluster Solution: Comparison of the four clusters in cognitive variables. Bonferroni-adjusted p-values are shown in the plots. Significance is displayed with stars as follows:this: $*p < .05$, $**p < .01$, $***p < .001$. Dunn's test was used for pairwise group comparisons. PVT: Psychomotor Vigilance Task, TMT: Trail Making Test.

No significant differences were found between clusters in demographic or questionnaire variables (Table 2). However, participants in C4 showed a mean FACIT-F score of 28.9 (SD = 10.75), indicating clinically relevant fatigue. No elevated levels of anxiety or depression were observed at the cluster level. However, mean PSQI scores across all clusters indicated overall poor sleep quality.

Due to the small sample sizes of subgroups within each cluster, no statistical comparisons were conducted between the eight subgroups. Descriptively, the participant with *no self-reported CD* in C4 had a fatigue score of 21, along with elevated depression (score = 8) and anxiety (score = 11). The MoCA score was normal in that participant.

The clusters of the two-cluster solution, as well as the clusters from the four-cluster solution, were also compared in their rsEEG delta and beta power.

EEG analysis

Data cleaning. Due to an empty dataset and file naming issues, two participants were excluded from the analysis, resulting in a final sample size of 68 participants, with one less in each cluster in the two-cluster solution (C1: n = 40, C2: n = 28) and one less in C2 (n = 28) and C4 (n = 7) in the four-cluster solution.

ICA artifact removal resulted in the retention of 86% of channels in C1 (M = 110.3, SD = 11.4, range = 75–125) and 85% in C2 (M = 109, SD = 11.0, range = 78–124) in the two-cluster solution. In the four-cluster solution, ICA artifact removal retained 86% of channels in C1 (M = 110.8, SD = 11.84), 85% in C2 (M = 109, SD = 11.03) and C3 (M = 108.6, SD = 12.19), and 88% in C4 (M = 113, SD = 6.64); ranges were 75–125, 78–124, 77–122, and 105–123, respectively. Following the additional artifact removal step, which included the exclusion of outlier channels, 84% of channels were retained in C1 (M = 108, SD = 11.2, range = 73–121) and 83% in C2 (M = 106.6, SD = 10.9, range = 77–121) in the two-cluster solution. In the four-cluster solution, 85% of channels remained in C1 (M = 108.4, SD = 11.46, range = 73–121), 83% in C2 (M = 106.6, SD = 10.92, range = 77–121), 83% in C3 (M = 106.3, SD = 12.17, range = 74–120), and 86% in C4 (M = 111.1, SD = 6.20, range = 104–121).

To maintain an adequate trial count while achieving higher temporal resolution, continuous EEG data were segmented into 5-second non-overlapping epochs. This resulted in an average of 37.7 good epochs (SD = 14.7, range = 4–60) in C1 and 37.9 (SD = 16.6, range = 3–59) in C2 in the two-cluster solution. In the four-cluster solution, the average number of good epochs was

37.6 in C1 (*SD* = 16.2, range = 4–58), 37.9 in C2 (*SD* = 16.6, range = 3–59), 35.9 in C3 (*SD* = 14.5, range = 9–60), and 42 in C4 (*SD* = 12.5, range = 24–60)

Beta Power (central ROI) in the Two-Cluster solution. In the two-cluster solution, mean beta power did not significantly differ between C1 (*M* = 1.64, *SD* = 1.43) and C2 (*M* = 1.86, *SD* = 1.75), as indicated by a two-sided Wilcoxon rank-sum test, $z = -.112$, $p = .9107$, $r = .0136$.

When considering both cluster affiliation and self-reported CD, beta power was highest in individuals with *self-reported CD (C2)* (*M* = 2.44, *SD* = 2.41), followed by those with *no self-reported CD (C1)* (*M* = 2.1, *SD* = 2.18). Lower beta power was observed in individuals with *no self-reported CD (C2)* (*M* = 1.56, *SD* = 1.39) and those with *self-reported CD (C1)* (*M* = 1.53, *SD* = 1.22). Pairwise Wilcoxon rank-sum tests comparing central beta power across these four groups revealed no statistically significant differences after Bonferroni correction (all p_adj = 1.00, $r = .03$ - $.19$) (Figure 6).

Delta Power (frontal ROI) in the Two-Cluster Solution. In the two-cluster solution, mean delta power did not significantly differ between C1 (*M* = 1.11, *SD* = 1.21) and C2 (*M* = 1.15, *SD* = .87), as indicated by a one-sided Wilcoxon rank-sum test, $z = -.735$, $p = .2311$, $r = .089$ (Figure 5).

When accounting for both cluster affiliation and self-reported CD, delta power was highest in participants with no self-reported CD group in C1 (*M* = 1.94, *SD* = 1.38), followed by those with self-reported CD in C2 (*M* = 1.48, *SD* = 1.08), and those with no self-reported CD in C2 (*M* = .94, *SD* = .75). Delta power was lowest in those with self-reported CD in C1 (*M* = .91, *SD* = .97). Pairwise Wilcoxon rank-sum tests revealed no significant differences in mean delta power between these four groups after Bonferroni correction (all p_adj > .05). However, an uncorrected difference was observed between participants with self-reported CD and no self-reported CD in C1 ($p = .031$, $r = .34$, moderate effect), but this did not survive correction (Figure 6).

Figure 5. Results of the power analysis in the (A) delta (0.6–4 Hz) and (B) beta (14–30 Hz) frequency bands for Cluster 1 and Cluster 2. The topographic map shows the distribution of (A) delta and (B) beta activity on the scalp for Cluster 1 and Cluster 2. White dots indicate the respective regions of interest (ROIs).


Figure 6. Results of the power analysis in the (A) delta (0.6–4 Hz) and (B) beta (14–30 Hz) frequency bands for the self-reported and no self-reported groups and clusters.

Beta and Delta Power in the Four-cluster solution. Relative delta and beta power in the central region were examined across the four EEG clusters to explore potential differences in spectral characteristics. Descriptively, C1 exhibited the highest average delta power (M = 1.34, SD = 1.34), followed by C2 (M = 1.15, SD = 0.87), C4 (M = 0.998, SD = 1.18), and C3 (M = 0.91, SD = 0.78). In contrast, beta power was lowest in C1 (M = 1.43, SD = 1.41) and highest in C3 (M = 1.97, SD = 1.72), with intermediate values observed in C2 (M = 1.86, SD = 1.75) and C4 (M = 1.62, SD = 1.43).

However, non-parametric Kruskal–Wallis tests indicated that these differences were not statistically significant. For relative beta power, the test yielded $\chi^2(3)$ = 0.93, p = .819; for relative delta power, $\chi^2(3)$ = 1.12, p = .772.

Further comparisons across the eight subgroups, defined by self-reported CD within each cluster, were not statistically investigated, as the subgroups were too small for comparison.

Correlation with clinical data

Central beta power was significantly correlated with TMT-A performance ($p(66)$ = .27 ,p = .025) in a Spearman Rank correlation (Table 3). A trend towards a positive correlation with TMT-B was also observed ($p(66)$ = .21, p = .09). Frontal delta power did not show significant correlations with any of the examined variables.

PVT reaction time correlated significantly negatively with the FACIT-F score ($p(66)$ = -.28, p = 0.02). A trend towards a positive correlation between PVT reaction time and PSQI score was also observed ($p(66)$ = .26, p = .05).

Table 3

Correlation of delta and beta power with cognitive tests and clinical health parameters

Variable	δ	β	TMT A	TMT B	PVT	PSQI	FACIT	HADS A	HADS D	MoCA
δ	1									
β	.06	1								
TMT A	-.06	**.27***	1							
TMT B	.03	.21	**.72*****	1						
PVT	.06	.04	**.47*****	**.33****	1					
PSQI	.20	-.11	.14	.08	.26	1				
FACIT	-.17	.003	-.09	-.08	**-.28***	**-.72*****	1			
HADS A	.20	-.02	.19	.10	.14	**.68*****	**-.70*****	1		
HADS D	.15	.01	.21	.19	.15	**.59*****	**-.77*****	**.64*****	1	
MoCA	-.02	-.18	-38**	**-.46*****	**-.40*****	-.01	.02	-.05	-.11	1

Note. *p < .05, **p < .01, ***p < .001. δ = delta power, *β* = beta power, TMT: Trail Making Test, PVT: Psychomotor Vigilance Task, PSQI: Pittsburgh Sleep Quality Index, FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue Scale, HADS: Hospital Anxiety and Depression Scale, MoCA: Montreal Cognitive Assessment

Discussion

This study aimed to investigate the cognitive and electrophysiological profiles of individuals exhibiting self-reported CD through hierarchical cluster analysis. The primary goal was to explore how these individuals differ in cognitive performance and EEG characteristics, particularly in terms of delta and beta power, and how these relate to measures of fatigue, anxiety, depression, and sleep quality.

The main findings indicate that the two-cluster solution revealed significant differences in cognitive performance, with C2 outperforming C1 across all cognitive variables. Within C2, participants with self-reported CD exhibited the highest levels of fatigue and anxiety. The four-cluster solution further differentiated cognitive performance, with C4 displaying the poorest cognitive performance and the highest fatigue scores. While questionnaire variables did not significantly differ between clusters in either solution, closer examination of self-reported vs. non-self-reported CD groups within clusters revealed differences. EEG analysis did not show significant differences in beta or delta power between clusters. However, beta power correlated with TMT-A performance, and PVT reaction time was associated with fatigue.

Cognitive performance

The hierarchical clustering approach revealed distinct patterns in cognitive performance. In the two-cluster solution, individuals with lower cognitive performance in the PVT, TMT-A, and n-back tasks were grouped into C1. In contrast, individuals in C2 performed significantly better in these cognitive measures than those in C1. In the four-cluster solution, participants in C2 exhibited the highest overall cognitive performance, significantly outperforming all other clusters across all cognitive tests. In contrast, participants in C4 demonstrated the lowest performance across all cognitive measures, with significantly lower scores in all tests compared to those in C2.

TMT. Normative test data for the TMT defines normal cognitive performance in the age group 45–54 years as a TMT-A completion time of 21.85–41.71 seconds and a TMT-B completion time of 49.34–78.18 seconds (Tombaugh, 2004). This indicates that while C1 performed worse than C2, their performance still falls within the normal cognitive range, suggesting no global cognitive impairment based on TMT measures. Moreover, C2 appears to be a high-achieving group, as they completed both TMT tasks faster than the normal completion range (TMT-A: $M = 19.5$, $SD = 4.0$; TMT-B: $M = 42$, $SD = 10.5$).

In the four-cluster solution, C4 demonstrated a mean completion time of 88.4 seconds ($SD = 34.3$) on the TMT-B, indicating an abnormally prolonged completion time compared to individuals in the same age group. This exceeds the normal completion range for TMT-B in this population, suggesting impairments in cognitive domains related to processing speed and executive functioning (Lezak, 1995; Mitrushina et al., 2005; Sánchez-Cubillo et al., 2009; Strauss et al., 2016; Tombaugh, 2004), as well as visual search and mental flexibility (Sánchez-Cubillo et al., 2009; Tombaugh, 2004), which are reflected in TMT-B performance.

PVT. Regarding the PVT, no normative data are available that establish normal and abnormal reaction time ranges in relation to age. When analyzing PVT reaction time data, most studies define a reaction time threshold of 500 ms to delineate lapses from normal responses and use this as a comparison metric (Gabel, Kass, Joyce, Spitschan, & Zeitzer, 2019; Lee, Bardwell, Ancoli-Israel, & Dimsdale, 2010). However, in this study, lapses were not calculated, making it impossible to directly compare the results to previous studies or to determine whether the observed PVT scores fall within normal or abnormal ranges.

One study examined average reaction times in a sample of eight healthy individuals and 40 individuals with sleep apnea, with mean ages of 49.5 years ($SD = 9.23$) and 49.15 years ($SD = $

9.51), respectively, similar to the age group in this study. The mean reaction times reported were 288.01 ms (SD = 52.33) for the healthy participants and 264.78 ms (SD = 42.85) for the apneic group (Lee et al., 2010). In comparison, the reaction times observed in all clusters (both in the two-cluster and four-cluster solutions) were higher than those reported in Lee et al. (2010). Specifically, reaction times in C1 (M = 357 ms) in the two-cluster solution, as well as in C1 (M = 357 ms) and C4 (M = 420 ms) in the four-cluster solution, were markedly slower. This suggests a general slowing of reaction time, not only within the study sample but also in comparison to external cohorts. However, statistical significance was not tested, and further research is needed to establish clear normative and abnormal ranges for PVT reaction times.

As all clusters (in both the two-cluster and four-cluster solutions) exhibited poor sleep quality based on PSQI scores, a generally slower reaction time in the PVT compared to other cohorts is plausible. This aligns with previous findings indicating that PVT performance is sensitive to sleepiness and affected by sleep deprivation (Drummond et al., 2005; Molina et al., 2019).

TMT and PVT. Interestingly, in the four-cluster solution, individuals from C1 performed significantly worse on the PVT than those from C3, but at the same time, performed significantly better on the TMT-B than individuals in C3. This suggests that different cognitive domains may be impaired in these patients. Specifically, C1 might experience more difficulties with sustained attention (Drummond et al., 2005), while individuals in C3 may struggle with cognitive domains related to TMT-B performance, such as processing speed, executive functioning (Lezak, 1995; Mitrushina et al., 2005; Sánchez-Cubillo et al., 2009; Strauss et al., 2016; Tombaugh, 2004), visual search, or mental flexibility (Sánchez-Cubillo et al., 2009; Tombaugh, 2004). Alternatively, this could be positively framed: C1 might have a strength in sustained attention, while C3 individuals might excel in the cognitive domains assessed by the TMT-B. Both groups did not differ significantly on questionnaire variables; however, C1 had a lower, though not clinically relevant, fatigue score and poorer sleep quality compared to C3.

MoCA. When examining the MoCA test results, 9 participants in the lower-performing cluster and 2 participants in the higher-performing cluster (C2) had a score indicative of clinically significant cognitive impairment. Notably, all 9 participants with an impaired MoCA score also reported cognitive decline (CD).

In this study, only the global MoCA score was used. However, it would have been valuable to analyze the sub-scores of different cognitive domains within the MoCA to determine whether

specific cognitive patterns emerge that may be particularly relevant to subjective and objective impairment in PCS patients. While the MoCA score can serve as a useful screening tool for cognitive assessment, it should not be the sole criterion for diagnosing cognitive impairment (Petersen, 2016). Instead, the MoCA can help identify which cognitive domains are specifically affected (Petersen, 2016). Therefore, investigating the subdomain scores of the MoCA could provide more meaningful insights than relying solely on the global score

Subjective cognitive CD versus objective cognitive impairment

The first hypothesis posited that individuals with objectively lower cognitive performance would report more frequent cognitive difficulties (CD) compared to those with higher objective performance. Of the 43 participants who self-reported CD, 33 were in the lower performing cluster (C1), while 10 were in the better performing cluster (C2), resulting in a sensitivity of 76.7%. Among the participants who did not report CD, 19 were in the better performing cluster (C2) and 8 were in the lower performing cluster (C1), yielding a specificity of 70.4%. However, these results should be interpreted with caution, as the classification may be misleading. Participants were specifically asked before the examination whether they experienced CD as a result of their SARS-CoV-2 infection. This means that individuals who had been experiencing CD before the infection would be classified as participants with no self-reported CD, although the exact number of such participants is unknown. A possible explanation for not being identified as cognitively impaired despite reporting cognitive difficulties could be that these individuals possess a high level of cognitive functioning. While they may notice a decline, they still perform relatively well compared to others. Nevertheless, it was observed that most participants with self-reported CD were in the lower performing cluster (C1), and most participants without self-reported CD were in the better performing cluster (C2).

Self-reported CD and related symptoms

The second hypothesis sought to explain the observed discrepancy between objective and subjective CD in the study group by proposing that individuals who self-report CD but are not classified as low performers on objective cognitive assessments may have elevated levels of fatigue, anxiety, or depression. Indeed, individuals with self-reported CD who were not identified as lower performers on cognitive tests reported clinically relevant levels of anxiety and fatigue, whereas the other three groups did not show clinically significant scores on these two variables. No subgroup exhibited a clinically significant score for depression, but all groups, except for the no self-reported CD group in C2, showed poor sleep quality. Within this context, the self-reported CD subgroup in C2 had the highest average PSQI score. This supports

the assumption that subjectively perceived CD is related to elevated anxiety, fatigue, and sleep disturbances (Gomzyakova et al., 2022; Henneghan et al., 2022; Zamarian et al., 2024), and suggests that fatigue and anxiety may serve as explanatory factors when objective cognitive impairment is not confirmed. Interestingly, in the four-cluster solution, one individual in cluster 4 who did not report CD had a low fatigue score (21), a high anxiety score (11), and an elevated depression score (8), yet their MoCA score was normal.

Delta Power

The first hypothesis concerning delta power was that a decrease in delta power would be observed in patients with objectively lower cognitive performance compared to better performers. However, this hypothesis could not be confirmed in either the two-cluster or the four-cluster solution.

Delta appears to be a promising frequency band for investigating PCS patients, as previous studies have identified differences in this band (Cecchetti et al., 2022; Furlani et al., 2022; Kopańska et al., 2022; Ortelli et al., 2023). However, this study did not find significant differences between the clusters. When considering research on MCI and AD, this may not be surprising. In all observed variables, the clusters differed significantly only in cognitive performance measures. Cognitive impairment was not indicated based on the scores in the TMT. The findings on PCS patients in the studies mentioned above may not reflect objective cognitive impairment but rather associated symptoms.

Research on MCI and AD has shown that abnormalities in the form of increased delta power are associated with more advanced cognitive decline and are not typically seen at the onset of conditions like AD or MCI (Dringenberg, 2000; Elmståhl et al., 1994; Farina et al., 2020; Schreiter-Gasser, Gasser, & Ziegler, 1994), therefore it might not be surprising, that no difference in delta power was found between clusters. Especially, since no actual objective cognitive impairment was found in clusters. Theta power, on the other hand, appears to be the first frequency band to show abnormalities, most commonly an increase in power, in individuals with cognitive impairment (Dringenberg, 2000; Elmståhl et al., 1994; Schreiter-Gasser et al., 1994). Therefore, it may be particularly relevant to investigate the role of theta power in individuals suffering from PCS to examine the relationship between PCS and reported cognitive impairment more closely.

Regarding the second hypothesis concerning delta power, it was hypothesized that decreased delta power might be associated with higher levels of fatigue. Interestingly, the greatest difference in delta power was found between the self-reported CD and no self-reported

CD group within C1. The no self-reported CD group exhibited the highest delta power, whereas the self-reported CD group showed the lowest. This could further suggest, that delta power might not be related to CD but rather to associated symptoms. However, these two subgroups did not significantly differ in any of the assessed questionnaire variables and did not indicate clinically relevant fatigue, anxiety, or depression. Notably, the fatigue score was lower in the self-reported CD group within that cluster. Both subgroups had a clinically relevant score in the PSQI, indicating poor sleep quality. The self-reported CD group showed a higher PSQI score than the other subgroup, but significant differences were not found. No explanation could be found for the difference found. However, the difference was also not significant.

A study on Chronic Fatigue Syndrome (CFS), which might have a similar symptom pattern to PCS, found that ultra-slow delta power (0.5-0.8 Hz) during sleep is lower in CFS than in healthy control (Le Bon et al., 2012). Further investigations could be to analyze ultra-slow delta power, to distinguish between fatigue and cognitive impairment.

Beta power

The first hypothesis about beta power, which suggested that an increase in beta power would be observed in patients with objectively lower performance compared to better performers, could not be confirmed. There was no significant difference between the clusters in both the two-cluster solution and the four-cluster solution. Although no significant difference was found between the four subgroups in the two-cluster solution, interestingly, individuals with self-reported CD in the better-performing cluster (C2) exhibited the highest mean in beta power, while the self-reported CD group in the lower-performing cluster (C1) showed a decrease in beta power.

As suggested in the second hypothesis concerning beta power, an increase in beta power could be an indicator of experiencing subjective CD as a result of higher levels of anxiety and depression, but not of objective cognitive impairment. Individuals with self-reported CD in the better-performing cluster (C2) had a mean of 8 on the HADS-A, indicating elevated levels of anxiety. However, a mean of 8 is just at the threshold for clinically significant anxiety. Depression was not elevated in this group, but they did have the lowest score on the FACIT-F scale, indicating low levels of fatigue. This was also the only subgroup where clinically relevant fatigue was observed. This could suggest that an increase in beta power is more related to symptoms associated with perceived CD rather than objective cognitive impairment itself.

An increase in beta power in patients with anxiety has been reported in other studies (Wang et al., 2025). However, the finding that increased beta power might also be related to higher

fatigue levels contradicts the findings of Jab et al. (2009), where beta power significantly decreased in patients with induced fatigue. A similar result was found in a study by Li et al. (2020), where relative beta power was significantly decreased in both resting-state EEG and task-state EEG in patients with mental fatigue.

The observed difference between the self-reported CD groups with better and lower performance was not significant, so no conclusions can be made about the relationship between fatigue, anxiety, and beta power. However, it would be interesting to investigate this further. If it turns out that beta power increases in individuals with anxiety symptoms but decreases in those experiencing mental fatigue, what would be expected regarding beta power in participants who experience both anxiety and fatigue, which could have conflicting influences on beta power, as observed in that subgroup? Further analysis of different combinations of symptoms in PCS patients would be valuable.

In this study, no correlation was found between the FACIT-F score (a measure of fatigue), the HADS anxiety score, and beta power, indicating that fatigue and anxiety do not have a direct relationship with beta power.

As mentioned earlier, literature on beta power in PCS and diseases related to cognitive impairment is limited and scattered. However, beta connectivity appears to be more relevant and interesting when investigating PCS patients. Beta connectivity could be particularly valuable to explore, as studies have found abnormalities in beta connectivity when investigating fatigue and individuals with PCS (Buyukturkoglu et al., 2017; Wu et al., 2023).

Limitations

The study has several limitations. First, no information was provided regarding cognitive performance before SARS-CoV-2 infection, which could have been relevant for interpreting the results. Additionally, the severity of the infection could have provided valuable insights into whether symptom severity plays a role in the severity of PCS in patients.

Furthermore, there are multiple variants of the SARS-CoV-2 virus (Meinhardt et al., 2024), each of which may have different effects on the brain, as symptom burdens appear to vary across these variants. For example, the symptom burden was lower after the Omicron variant compared to the Delta variant (Antonelli et al., 2022). However, Omicron was first identified in December 2021 (Meinhardt et al., 2024), which was after the recruitment period for the COVIDOM study.

Only TMT completion time and reaction time were used as cluster variables in this study. Including additional cognitive variables that reflect different cognitive domains might have

provided further insights into which specific cognitive domains are impaired and how these impairments may be explained by biological factors and/or mental status.

Another limitation is that the gender of participants was not taken into account when calculating the power. Furthermore, the clusters were not equally balanced in terms of gender. Several studies have found gender-specific patterns in frequency bands, which should always be considered when investigating rsEEG (Cave & Berry, 2021; Jaušovec & Jaušovec, 2000; Tomescu et al., 2018).

EEG analysis does not follow a single, standardized guideline but instead involves selecting from a range of steps and parameters, many of which are data-driven (Delorme, 2023). As a result, analyzing the same data can potentially yield different outcomes depending on the chosen approach. This variability in analysis methods should be taken into consideration when interpreting EEG results, as it may influence the conclusions drawn from the data.

Further investigations

Besides the already mentioned possible further investigations along the discussion, it could be interesting to include more psychological symptoms into account, when investigating self-reported CD. Cecchetti et al. (2022) for example found PTBS to be quite present in PCS patients. In addition, it would be valuable to further explore how conditions such as depression and anxiety are not only associated with subjective cognitive difficulties (CD) but also with objective CD (Petersen, 2016).

This study focused solely on resting-state EEG, but when the goal is to identify specific brain patterns associated with particular cognitive domains, it would be of interest to also investigate event-related potentials (ERPs) (Babiloni, 2016).

Conclusion

The hierarchical clustering analysis revealed a two-cluster solution and a four-cluster solution, with the clusters differing only in their cognitive performance levels. Furthermore, this study suggests that psychological and other health-related factors, such as fatigue, anxiety, and sleep disturbances, can significantly contribute to the perception of cognitive difficulties, even in the absence of measurable cognitive impairments. EEG analysis did not reveal significant differences in delta or beta power between clusters, indicating that these frequency bands may be more closely associated with symptoms than with cognitive dysfunction itself. Further research is needed to explore the relationship between psychological symptoms, brain connectivity, and cognitive performance, as well as to refine the role of EEG in understanding the symptomatology of post-viral conditions like PCS.

References

Abdulrab, K., & Heun, R. (2008). Subjective Memory Impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria. *European Psychiatry*, *23*(5), 321–330. https://doi.org/10.1016/j.eurpsy.2008.02.004

Adler, G., Bramesfeld, A., & Jajcevic, A. (1999). Mild Cognitive Impairment in Old-Age Depression Is Associated with Increased EEG Slow-Wave Power. *Neuropsychobiology*, *40*(4), 218–222. https://doi.org/10.1159/000026623

Almeria, M., Cejudo, J. C., Sotoca, J., Deus, J., & Krupinski, J. (2020). Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. *Brain, Behavior, & Immunity-Health*, *9*, 100163. https://doi.org/10.1016/j.bbih.2020.100163

Amin-Chowdhury, Z., Harris, R. J., Aiano, F., Zavala, M., Bertran, M., Borrow, R., Linley, E., Ahmad, S., Parker, B., Horsley, A., & others. (2021). Characterising long COVID more than 6 months after acute infection in adults; prospective longitudinal cohort study, England. *medRxiv*, 2021–03. https://doi.org/10.1101/2021.03.18.21253633

Andrei Appelt, P., Taciana Sisconetto, A., Baldo Sucupira, K. S. M., Neto, E. D. M., Chagas, T. D. J., Bazan, R., Moura Cabral, A., Andrade, A. D. O., De Souza, L. A. P. S., & José Luvizutto, G. (2022). Changes in Electrical Brain Activity and Cognitive Functions Following Mild to Moderate COVID-19: A one-Year Prospective Study After Acute Infection. *Clinical EEG and Neuroscience*, *53*(6), 543–557. https://doi.org/10.1177/15500594221103834

Andrei Appelt, P., Taciana Sisconetto, A., Baldo Sucupira, K. S. M., Neto, E. de M., Chagas, T. de J., Bazan, R., Moura Cabral, A., Andrade, A. de O., de Souza, L. A. P. S., & José Luvizutto, G. (2022). Changes in electrical brain activity and cognitive functions following mild to moderate COVID-19: A one-year prospective study after acute infection. *Clinical EEG and Neuroscience*, *53*(6), 543–557. https://doi.org/10.1177/15500594221103834

Antony, A. R., & Haneef, Z. (2020). Systematic review of EEG findings in 617 patients diagnosed with COVID-19. *Seizure*, *83*, 234–241. https://doi.org/10.1016/j.seizure.2020.10.014

Arbuthnott, K., & Frank, J. (2000). Trail Making Test, Part B as a Measure of Executive Control: Validation Using a Set-Switching Paradigm. *Journal of Clinical and Experimental Neuropsychology*, *22*(4), 518–528. https://doi.org/10.1076/1380-3395(200008)22:4;1-0;FT518

Attar, E. T. (2022). Review of electroencephalography signals approaches for mental stress assessment. *Neurosciences Journal*, *27*(4), 209–215. https://doi.org/10.17712/nsj.2022.4.20220025

Babiloni, C., Arakaki, X., Bonanni, L., Bujan, A., Carrillo, M. C., Del Percio, C., Edelmayer, R. M., Egan, G., Elahh, F. M., Evans, A., & others. (2021). EEG measures for clinical research in major vascular cognitive impairment: Recommendations by an expert panel. *Neurobiology of Aging*, *103*, 78–97. https://doi.org/10.1016/j.neurobiolaging.2021.03.003

Babiloni, C., Lizio, R., Marzano, N., Capotosto, P., Soricelli, A., Triggiani, A. I., Cordone, S., Gesualdo, L., & Del Percio, C. (2016). Brain neural synchronization and functional coupling in Alzheimer's disease as revealed by resting state EEG rhythms. *International Journal of Psychophysiology*, *103*, 88–102. https://doi.org/10.1016/j.ijpsycho.2015.02.008

Babiloni, C., Vecchio, F., Lizio, R., Ferri, R., Rodriguez, G., Marzano, N., Frisoni, G. B., & Rossini, P. M. (2011). Resting state cortical rhythms in mild cognitive impairment and Alzheimer's disease: Electroencephalographic evidence. *Journal of Alzheimer's Disease*, *26*(s3), 201–214. https://doi.org/10.3233/JAD-2011-0051

Badinlou, F., Lundgren, T., & Jansson-Fröjmark, M. (2022). Mental health outcomes following COVID-19 infection: Impacts of post-COVID impairments and fatigue on depression, anxiety, and insomnia—A web survey in Sweden. *BMC Psychiatry*, *22*(1), 743. https://doi.org/10.1186/s12888-022-04405-0

Bahmer, T., Borzikowsky, C., Lieb, W., Horn, A., Krist, L., Fricke, J., Scheibenbogen, C., Rabe, K. F., Maetzler, W., Maetzler, C., & others. (2022). Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. *EClinicalMedicine*, *51*. https://doi.org/10.1016/j.eclinm.2022.101549

Barry, R. J., & De Blasio, F. M. (2017). EEG differences between eyes-closed and eyes-open resting remain in healthy ageing. *Biological Psychology*, *129*, 293–304. https://doi.org/10.1016/j.biopsycho.2017.09.010

Basner, M., & Dinges, D. F. (2011). Maximizing sensitivity of the psychomotor vigilance test (PVT) to sleep loss. *Sleep*, *34*(5), 581–591. https://doi.org/10.1093/sleep/34.5.581

Becker, J. H., Lin, J. J., Doernberg, M., Stone, K., Navis, A., Festa, J. R., & Wisnivesky, J. P. (2021). Assessment of cognitive function in patients after COVID-19 infection. *JAMA Network Open*, *4*(10), e2130645–e2130645. https://doi.org/10.1001/jamanetworkopen.2021.30645

Berger, H. (1929). Über das elektroenkephalogramm des menschen. *Archiv Für Psychiatrie Und Nervenkrankheiten*, *87*(1), 527–570. https://doi.org/10.1007/BF01797193

Besteher, B., Rocktäschel, T., Garza, A. P., Machnik, M., Ballez, J., Helbing, D.-L., Finke, K., Reuken, P., Güllmar, D., Gaser, C., & others. (2024). Cortical thickness alterations and systemic inflammation define long-COVID patients with cognitive impairment. *Brain, Behavior, and Immunity*, *116*, 175–184. https://doi.org/10.1016/j.bbi.2023.11.028

Biasiucci, A., Franceschiello, B., & Murray, M. M. (2019). Electroencephalography. *Current Biology*, *29*(3), R80–R85. https://doi.org/10.1016/j.cub.2018.11.052

Birle, C., Slavoaca, D., Balea, M., Livint Popa, L., Muresanu, I., Stefanescu, E., Vacaras, V., Dina, C., Strilciuc, S., Popescu, B. O., & others. (2021). Cognitive function: Holarchy or holacracy? *Neurological Sciences*, *42*, 89–99. https://doi.org/10.1007/s10072-020-04737-3

Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the Hospital Anxiety and Depression Scale: An updated literature review. *Journal of Psychosomatic Research*, *52*(2), 69–77. https://doi.org/10.1016/S0022-3999(01)00296-3

Blackmon, K., Day, G. S., Powers, H. R., Bosch, W., Prabhakaran, D., Woolston, D., & Pedraza, O. (2022). Neurocognitive screening in patients following SARS-CoV-2 infection: Tools for triage. *BMC Neurology*, *22*(1), 285. https://doi.org/10.1186/s12883-022-02817-9

Bland, A., Barraclough, M., Trender, W., Mehta, M., Hellyer, P., Hampshire, A., Penner, I.-K., Elliott, R., & Harenwall, S. (2024). Profiles of objective and subjective cognitive function in Post-COVID Syndrome, COVID-19 recovered, and COVID-19 naïve individuals. *Scientific Reports*, *14*(1), 13368. https://doi.org/10.1038/s41598-024-62050-x

Brück, E., Larsson, J. W., Lasselin, J., Bottai, M., Hirvikoski, T., Sundman, E., Eberhardson, M., Sackey, P., & Olofsson, P. S. (2019). Lack of clinically relevant correlation between subjective and objective cognitive function in ICU survivors: A prospective 12-month follow-up study. *Critical Care*, *23*, 1–11. https://doi.org/10.1186/s13054-019-2527-1

Buonsenso, D., Munblit, D., De Rose, C., Sinatti, D., Ricchiuto, A., Carfi, A., & Valentini, P. (2021). Preliminary evidence on long COVID in children. *Acta Paediatrica (Oslo, Norway: 1992)*, *110*(7), 2208. https://doi.org/10.1111/apa.15870

Butt, Z., Lai, J., Rao, D., Heinemann, A. W., Bill, A., & Cella, D. (2013). Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F) scale. *Journal of Psychosomatic Research*, *74*(1), 64–68. https://doi.org/10.1016/j.jpsychores.2012.10.011

Buysse, D. J., Reynolds III, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Research*, *28*(2), 193–213. https://doi.org/10.1016/0165-1781(89)90047-4

Cambridge Cognition. (2015, August 19). *What is cognition?* Cambridge Cognition. https://cambridgecognition.com/what-is-cognition/

Carpenter, J. S., & Andrykowski, M. A. (1998). Psychometric evaluation of the Pittsburgh sleep quality index. *Journal of Psychosomatic Research*, *45*(1), 5–13. https://doi.org/10.1016/S0022-3999(97)00298-5

Cave, A. E., & Barry, R. J. (2021). Sex differences in resting EEG in healthy young adults. *International Journal of Psychophysiology*, *161*, 35–43. https://doi.org/10.1016/j.ijpsycho.2021.01.008

Ceban, F., Ling, S., Lui, L. M., Lee, Y., Gill, H., Teopiz, K. M., Rodrigues, N. B., Subramaniapillai, M., Di Vincenzo, J. D., Cao, B., & others. (2022). Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain, Behavior, and Immunity*, *101*, 93–135. https://doi.org/10.1016/j.bbi.2021.12.020

Cecchetti, G., Agosta, F., Canu, E., Basaia, S., Barbieri, A., Cardamone, R., Bernasconi, M. P., Castelnovo, V., Cividini, C., Cursi, M., Vabanesi, M., Impellizzeri, M., Lazzarin, S. M., Fanelli, G. F., Minicucci, F., Giacalone, G., Falini, A., Falautano, M., Rovere-Querini, P., … Filippi, M. (2022). Cognitive, EEG, and MRI features of COVID-19 survivors: A 10-month study. *Journal of Neurology*, *269*(7), 3400–3412. https://doi.org/10.1007/s00415-022-11047-5

Cella, D., Lai, J., Chang, C.-H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general United States population. *Cancer*, *94*(2), 528–538. https://doi.org/10.1002/cncr.10245

Cella, D., Lenderking, W. R., Chongpinitchai, P., Bushmakin, A. G., Dina, O., Wang, L., Cappelleri, J. C., & Navarro-Compán, V. (2022). Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis. *Journal of Patient-Reported Outcomes*, *6*(1), 100. https://doi.org/10.1186/s41687-022-00508-0

Claus, J., Ongerboer de Visser, B., Bour, L., Walstra, G., Hijdra, A., Verbeeten Jr, B., Van Royen, E., Kwa, V., & Van Gool, W. (2000). Determinants of quantitative spectral electroencephalography in early Alzheimer's disease: Cognitive function, regional cerebral blood flow, and computed tomography. *Dementia and Geriatric Cognitive Disorders*, *11*(2), 81–89. https://doi.org/10.1159/000017219

Clemente, L., La Rocca, M., Quaranta, N., Iannuzzi, L., Vecchio, E., Brunetti, A., Gentile, E., Dibattista, M., Lobasso, S., Bevilacqua, V., & others. (2023). Prefrontal dysfunction in post-COVID-19 hyposmia: An EEG/fNIRS study. *Frontiers in Human Neuroscience*, *17*, 1240831. https://doi.org/10.3389/fnhum.2023.1240831

Corsi-Cabrera, M., Ramos, J., Arce, C., Guevara, M., Ponce-de León, M., & Lorenzo, I. (1992). Changes in the waking EEG as a consequence of sleep and sleep deprivation. *Sleep*, *15*(6), 550–555. https://doi.org/10.1093/sleep/15.6.550

Costas-Carrera, A., Sánchez-Rodríguez, M. M., Cañizares, S., Ojeda, A., Martín-Villalba, I., Primé-Tous, M., Rodríguez-Rey, M. A., Segú, X., Valdesoiro-Pulido, F., Borras, R., & others. (2022). Neuropsychological functioning in post-ICU patients after severe COVID-19 infection: The role of cognitive reserve. *Brain, Behavior, & Immunity-Health*, *21*, 100425. https://doi.org/10.1016/j.bbih.2022.100425

D'Amelio, M., & Rossini, P. M. (2012). Brain excitability and connectivity of neuronal assemblies in Alzheimer's disease: From animal models to human findings. *Progress in Neurobiology*, *99*(1), 42–60. https://doi.org/10.1016/j.pneurobio.2012.07.001

Damiano, R. F., Guedes, B. F., de Rocca, C. C., de Pádua Serafim, A., Castro, L. H. M., Munhoz, C. D., Nitrini, R., Filho, G. B., Miguel, E. C., Lucchetti, G., & others. (2022). Cognitive decline following acute viral infections: Literature review and projections for post-COVID-19. *European Archives of Psychiatry and Clinical Neuroscience*, *272*(1), 139–154. https://doi.org/10.1007/s00406-021-01286-4

Darley, D. R., Dore, G. J., Byrne, A. L., Plit, M. L., Brew, B. J., Kelleher, A., & Matthews, G. V. (2021). Limited recovery from post-acute sequelae of SARS-CoV-2 at 8 months in a prospective cohort. *ERJ Open Research*, *7*(4). https://doi.org/10.1183/23120541.00384-2021

D'Atri, A., Scarpelli, S., Gorgoni, M., Truglia, I., Lauri, G., Cordone, S., Ferrara, M., Marra, C., Rossini, P. M., & De Gennaro, L. (2021). EEG alterations during wake and sleep in mild cognitive impairment and Alzheimer's disease. *Iscience*, *24*(4). https://doi.org/10.1016/j.isci.2021.102386

Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re'em, Y., Redfield, S., Austin, J. P., & Akrami, A. (2021). Characterizing long COVID in an international cohort: 7 months of

symptoms and their impact. *EClinicalMedicine*, *38*. https://doi.org/10.1016/j.eclinm.2021.101019

De Gennaro, L., Marzano, C., Veniero, D., Moroni, F., Fratello, F., Curcio, G., Ferrara, M., Ferlazzo, F., Novelli, L., Pellicciari, M. C., & others. (2007). Neurophysiological correlates of sleepiness: A combined TMS and EEG study. *Neuroimage*, *36*(4), 1277–1287. https://doi.org/10.1016/j.neuroimage.2007.04.013

Delgado-Alonso, C., Valles-Salgado, M., Delgado-Álvarez, A., Yus, M., Gómez-Ruiz, N., Jorquera, M., Polidura, C., Gil, M. J., Marcos, A., Matías-Guiu, J., & others. (2022). Cognitive dysfunction associated with COVID-19: A comprehensive neuropsychological study. *Journal of Psychiatric Research*, *150*, 40–46. https://doi.org/10.1016/j.jpsychires.2022.03.033

Delorme, A. (2023). EEG is better left alone. *Scientific Reports*, *13*(1), 2372. https://doi.org/10.1038/s41598-023-27528-0

Deng, J., Zhou, F., Hou, W., Silver, Z., Wong, C. Y., Chang, O., Huang, E., & Zuo, Q. K. (2021). The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: A meta-analysis. *Annals of the New York Academy of Sciences*, *1486*(1), 90–111. https://doi.org/10.1111/nyas.14506

Dierks, T., Frölich, L., Ihl, R., & Maurer, K. (1995). Correlation between cognitive brain function and electrical brain activity in dementia of Alzheimer type. *Journal of Neural Transmission/General Section JNT*, *99*, 55–62. https://doi.org/10.1007/BF01271469

Díez-Cirarda, M., Yus-Fuertes, M., Sanchez-Sanchez, R., Gonzalez-Rosa, J. J., Gonzalez-Escamilla, G., Gil-Martínez, L., Delgado-Alonso, C., Gil-Moreno, M. J., Valles-Salgado, M., Cano-Cano, F., & others. (2023). Hippocampal subfield abnormalities and biomarkers of pathologic brain changes: From SARS-CoV-2 acute infection to post-COVID syndrome. *EBioMedicine*, *94*. https://doi.org/10.1016/j.ebiom.2023.104711

Dringenberg, H. C. (2000). Alzheimer's disease: More than a 'cholinergic disorder'—Evidence that cholinergic–monoaminergic interactions contribute to EEG slowing and dementia. *Behavioural Brain Research*, *115*(2), 235–249. https://doi.org/10.1016/S0166-4328(00)00261-8

Drummond, S. P. A., Bischoff-Grethe, A., Dinges, D. F., Ayalon, L., Mednick, S. C., & Meloy, M. J. (2005). The Neural Basis of the Psychomotor Vigilance Task. *Sleep*. https://doi.org/10.1093/sleep/28.9.1059

Elkan, M., Dvir, A., Zaidenstein, R., Keller, M., Kagansky, D., Hochman, C., & Koren, R. (2021). Patient-reported outcome measures after hospitalization during the COVID-19 pandemic: A survey among COVID-19 and non-COVID-19 patients. *International Journal of General Medicine*, 4829–4836. https://doi.org/10.2147/IJGM.S323316

Elmståhl, S., Rosén, I., & Gullberg, B. (1994). Quantitative EEG in elderly patients with Alzheimer's disease and healthy controls. *Dementia and Geriatric Cognitive Disorders*, *5*(2), 119–124. https://doi.org/10.1159/000106706

Eysenck, M. W., & Brysbaert, M. (2018). *Fundamentals of cognition*. Routledge. https://doi.org/10.4324/9781315617633

Farina, F. R., Emek-Savaş, D., Rueda-Delgado, L., Boyle, R., Kiiski, H., Yener, G., & Whelan, R. (2020). A comparison of resting state EEG and structural MRI for classifying Alzheimer's disease and mild cognitive impairment. *Neuroimage*, *215*, 116795. https://doi.org/10.1016/j.neuroimage.2020.116795

Ferrucci, R., Dini, M., Groppo, E., Rosci, C., Reitano, M. R., Bai, F., Poletti, B., Brugnera, A., Silani, V., D'Arminio Monforte, A., & others. (2021). Long-lasting cognitive abnormalities after COVID-19. *Brain Sciences*, *11*(2), 235. https://doi.org/10.3390/brainsci11020235

Finnigan, S., & Robertson, I. H. (2011). Resting EEG theta power correlates with cognitive performance in healthy older adults. *Psychophysiology*, *48*(8), 1083–1087. https://doi.org/10.1111/j.1469-8986.2010.01173.x

Fortini, A., Torrigiani, A., Sbaragli, S., Lo Forte, A., Crociani, A., Cecchini, P., Innocenti Bruni, G., & Faraone, A. (2021). COVID-19: Persistence of symptoms and lung alterations after 3–6 months from hospital discharge. *Infection*, *49*, 1007–1015. https://doi.org/10.1007/s15010-021-01638-1

Freitas, S., Simões, M. R., Alves, L., & Santana, I. (2013). Montreal cognitive assessment: Validation study for mild cognitive impairment and Alzheimer disease. *Alzheimer Disease & Associated Disorders*, *27*(1), 37–43. https://doi.org/10.1097/WAD.0b013e3182420bfe

Froelich, L., Lladó, A., Khandker, R. K., Pedrós, M., Black, C. M., Sánchez Díaz, E. J., Chekani, F., & Ambegaonkar, B. (2021). Quality of life and caregiver burden of Alzheimer's disease among community dwelling patients in Europe: Variation by disease severity and progression. *Journal of Alzheimer's Disease Reports*, *5*(1), 791–804. https://doi.org/10.3233/ADR-210025

Furlanis, G., Buoite Stella, A., Biaduzzini, F., Bellavita, G., Frezza, N. A., Olivo, S., Menichelli, A., Lunardelli, A., Ajčević, M., & Manganotti, P. (2023). Cognitive deficit in post-acute COVID-19: An opportunity for EEG evaluation? *Neurological Sciences*, *44*(5), 1491–1498. https://doi.org/10.1007/s10072-023-06615-0

Gabel, V., Kass, M., Joyce, D. S., Spitschan, M., & Zeitzer, J. M. (2019). Auditory psychomotor vigilance testing in older and young adults: A revised threshold setting procedure. *Sleep and Breathing*, *23*, 1021–1025. https://doi.org/10.1007/s11325-019-01859-7

García-Sánchez, C., Calabria, M., Grunden, N., Pons, C., Arroyo, J. A., Gómez-Anson, B., Lleó, A., Alcolea, D., Belvís, R., Morollón, N., & others. (2022). Neuropsychological deficits in patients with cognitive complaints after COVID-19. *Brain and Behavior*, *12*(3), e2508. https://doi.org/10.1002/brb3.2508

Gaudino, E. A., Geisler, M. W., & Squires, N. K. (1995). Construct validity in the Trail Making Test: What makes Part B harder? *Journal of Clinical and Experimental Neuropsychology*, *17*(4), 529–535. https://doi.org/10.1080/01688639508405143

Gomzyakova, N. A, Palchikova, E. I., Tumova, M. A., Kasyanov, E. D., & Sorokin, M. Y. (2022). Association of anxiety and depression with objective and subjective cognitive decline in outpatient healthcare consumers with COVID-19: A cross-sectional study. *Consortium Psychiatricum*, *3(3)*, 46–57. https://doi.org/10.17816/CP189

González-Hermosillo, J. A., Martínez-López, J. P., Carrillo-Lampón, S. A., Ruiz-Ojeda, D., Herrera-Ramírez, S., Amezcua-Guerra, L. M., & Martínez-Alvarado, M. del R. (2021). Post-acute COVID-19 symptoms, a potential link with myalgic encephalomyelitis/chronic fatigue syndrome: A 6-month survey in a Mexican cohort. *Brain Sciences*, *11*(6), 760. https://doi.org/10.3390/brainsci11060760

Gorgoni, M., Ferlazzo, F., Ferrara, M., Moroni, F., D'Atri, A., Fanelli, S., Torriglia, I. G., Lauri, G., Marzano, C., Rossini, P. M., & others. (2014). Topographic electroencephalogram changes associated with psychomotor vigilance task performance after sleep deprivation. *Sleep Medicine*, *15*(9), 1132–1139. https://doi.org/10.1016/j.sleep.2014.04.022

Güntekin, B., Emek-Savaş, D. D., Kurt, P., Yener, G. G., & Başar, E. (2013). Beta oscillatory responses in healthy subjects and subjects with mild cognitive impairment. *NeuroImage: Clinical*, *3*, 39–46. https://doi.org/10.1016/j.nicl.2013.07.003

Harmony, T. (2013). The functional significance of delta oscillations in cognitive processing. *Frontiers in Integrative Neuroscience*, *7*, 83. https://doi.org/10.3389/fnint.2013.00083

Hasting, A. S., Herzig, S., Obrig, H., Schroeter, M. L., Villringer, A., & Thöne-Otto, A. I. (2023). The Leipzig treatment program for interdisciplinary diagnosis and therapy of neurocognitive post-COVID symptoms. *Zeitschrift Für Neuropsychologie*. https://doi.org/10.1024/1016-264X/a000376

Heine, J., Schwichtenberg, K., Hartung, T. J., Rekers, S., Chien, C., Boesl, F., Rust, R., Hohenfeld, C., Bungenberg, J., Costa, A. S., & others. (2023). Structural brain changes in patients with post-COVID fatigue: A prospective observational study. *EClinicalMedicine*, *58*. https://doi.org/10.1016/j.eclinm.2023.101874

Henneghan, A. M., Lewis, K. A., Gill, E., & Kesler, S. R. (2022). Cognitive impairment in non-critical, mild-to-moderate COVID-19 survivors. *Frontiers in Psychology*, *13*, 770459. https://doi.org/10.3389/fpsyg.2022.770459

Herrero, M. J., Blanch, J., Peri, J. M., De Pablo, J., Pintor, L., & Bulbena, A. (2003). A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. *General Hospital Psychiatry*, *25*(4), 277–283. https://doi.org/10.1016/S0163-8343(03)00043-4

Herrmann, C. (1997). International experiences with the Hospital Anxiety and Depression Scale-a review of validation data and clinical results. *Journal of Psychosomatic Research*, *42*(1), 17–41. https://doi.org/10.1016/S0022-3999(96)00216-4

Hill, N. L., Mogle, J., Wion, R., Munoz, E., DePasquale, N., Yevchak, A. M., & Parisi, J. M. (2016). Subjective cognitive impairment and affective symptoms: A systematic review. *The Gerontologist*, *56*(6), e109–e127. https://doi.org/10.1093/geront/gnw091

Hinz, A., & Brähler, E. (2011). Normative values for the hospital anxiety and depression scale (HADS) in the general German population. *Journal of Psychosomatic Research*, *71*(2), 74–78. https://doi.org/10.1016/j.jpsychores.2011.01.005

Hinz, A., Glaesmer, H., Brähler, E., Löffler, M., Engel, C., Enzenbach, C., Hegerl, U., & Sander, C. (2017). Sleep quality in the general population: Psychometric properties of the Pittsburgh Sleep Quality Index, derived from a German community sample of 9284 people. *Sleep Medicine*, *30*, 57–63. https://doi.org/10.1016/j.sleep.2016.03.008

Hobson, J. (2015). The montreal cognitive assessment (MoCA). *Occupational Medicine*, *65*(9), 764–765. https://doi.org/10.1093/occmed/kqv078

Hogan, M. J., Swanwick, G. R., Kaiser, J., Rowan, M., & Lawlor, B. (2003). Memory-related EEG power and coherence reductions in mild Alzheimer's disease. *International Journal of Psychophysiology*, *49*(2), 147–163. https://doi.org/10.1016/S0167-8760(03)00118-1

Holdsworth, D. A., Chamley, R., Barker-Davies, R., O'Sullivan, O., Ladlow, P., Mitchell, J. L., Dewson, D., Mills, D., May, S. L., Cranley, M., & others. (2022). Comprehensive clinical

assessment identifies specific neurocognitive deficits in working-age patients with long-COVID. *PLoS One*, *17*(6), e0267392. https://doi.org/10.1371/journal.pone.0267392

Horn, A., Krist, L., Lieb, W., Montellano, F., Kohls, M., Haas, K., Gelbrich, G., Bolay-Gehrig, S., Morbach, C., Reese, J., & others. (2021). Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: Design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP). *Infection*, *49*, 1277–1287. https://doi.org/10.1007/s15010-021-01707-5

Jaeggi, S. M., Buschkuehl, M., Perrig, W. J., & Meier, B. (2010). The concurrent validity of the N-back task as a working memory measure. *Memory*, *18*(4), 394–412.

Jakobsen, L. H., Sorensen, J. M., Rask, I. K., Jensen, B. S., & Kondrup, J. (2011). Validation of reaction time as a measure of cognitive function and quality of life in healthy subjects and patients. *Nutrition*, *27*(5), 561–570. https://doi.org/10.1016/j.nut.2010.08.003

Jap, B. T., Lal, S., Fischer, P., & Bekiaris, E. (2009). Using EEG spectral components to assess algorithms for detecting fatigue. *Expert Systems with Applications*, *36*(2), 2352–2359. https://doi.org/10.1016/j.eswa.2007.12.043

Jaušovec, N., & Jaušovec, K. (2010). Resting brain activity: Differences between genders. *Neuropsychologia*, *48*(13), 3918–3925. https://doi.org/10.1016/j.neuropsychologia.2010.09.020

Jelic, V., Johansson, S. E., Almkvist, O., Shigeta, M., Julin, P., Nordberg, A., Winblad, B., & Wahlund, L. O. (2000). Quantitative electroencephalography in mild cognitive impairment: Longitudinal changes and possible prediction of Alzheimer's disease. *Neurobiology of Aging*, *21*(4), 533–540. https://doi.org/10.1016/S0197-4580(00)00153-6

Jelic, V., Shigeta, M., Julin, P., Almkvist, O., Winblad, B., & Wahlund, L.-O. (1996). Quantitative electroencephalography power and coherence in Alzheimer's disease and mild cognitive impairment. *Dementia and Geriatric Cognitive Disorders*, *7*(6), 314–323. https://doi.org/10.1159/000106897

Jeong, J. (2004). EEG dynamics in patients with Alzheimer's disease. *Clinical Neurophysiology*, *115*(7), 1490–1505. https://doi.org/10.1016/j.clinph.2004.01.001

Kane, M. J., Conway, A. R. A., Miura, T. K., & Colflesh, G. J. H. (2007). Working memory, attention control, and the n-back task: A question of construct validity. *Journal of Experimental Psychology: Learning, Memory, and Cognition*, *33*(3), 615–622. https://doi.org/10.1037/0278-7393.33.3.615

Kang, J. M., Cho, Y.-S., Park, S., Lee, B. H., Sohn, B. K., Choi, C. H., Choi, J.-S., Jeong, H. Y., Cho, S.-J., Lee, J.-H., & others. (2018). Montreal cognitive assessment reflects cognitive reserve. *BMC Geriatrics*, *18*, 1–8. https://doi.org/10.1186/s12877-018-0951-8

Kim, S.-E., Shin, C., Yim, J., Seo, K., Ryu, H., Choi, H., Park, J., & Min, B.-K. (2023). Resting-state electroencephalographic characteristics related to mild cognitive impairments. *Frontiers in Psychiatry*, *14*, 1231861. https://doi.org/10.3389/fpsyt.2023.1231861

Kirchner, W. K. (1958). Age differences in short-term retention of rapidly changing information. *Journal of Experimental Psychology*, *55*(4), 352.

Koenig, T., Smailovic, U., & Jelic, V. (2020). Past, present and future EEG in the clinical workup of dementias. *Psychiatry Research: Neuroimaging*, *306*, 111182. https://doi.org/10.1016/j.pscychresns.2020.111182

Kopańska, M., Ochojska, D., Muchacka, R., Dejnowicz-Velitchkov, A., Banaś-Ząbczyk, A., & Szczygielski, J. (2022). Comparison of QEEG Findings before and after Onset of Post-COVID-19 Brain Fog Symptoms. *Sensors*, *22*(17), 6606. https://doi.org/10.3390/s22176606

Kubota, T., Gajera, P. K., & Kuroda, N. (2021). Meta-analysis of EEG findings in patients with COVID-19. *Epilepsy & Behavior*, *115*, 107682. https://doi.org/10.1016/j.yebeh.2020.107682

Kwan, A. T., Lakhani, M., Le, G. H., Singh, G., Teopiz, K. M., Ceban, F., Nijjar, C. S., Meshkat, S., Badulescu, S., Ho, R., & others. (2024). Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: A secondary analysis of a

Randomized Controlled Trial. *European Archives of Psychiatry and Clinical Neuroscience*, 1–8. https://doi.org/10.1007/s00406-024-01877-x

Lamond, N., Jay, S. M., Dorrian, J., Ferguson, S. A., Roach, G. D., & Dawson, D. (2008). The sensitivity of a palm-based psychomotor vigilance task to severe sleep loss. *Behavior Research Methods*, *40*(1), 347–352. https://doi.org/10.3758/BRM.40.1.347

Larouche, E., Tremblay, M.-P., Potvin, O., Laforest, S., Bergeron, D., Laforce, R., Monetta, L., Boucher, L., Tremblay, P., Belleville, S., & others. (2016). Normative data for the Montreal Cognitive Assessment in middle-aged and elderly Quebec-French people. *Archives of Clinical Neuropsychology*, *31*(7), 819–826. https://doi.org/10.1093/arclin/acw076

Latronico, N., Peli, E., Rodella, F., Novelli, M. P., Rasulo, F. A., Piva, S., & Center, L. (2020). Six-month outcome in survivors of COVID-19 associated acute respiratory distress syndrome. *Six-Month Outcome in Survivors of COVID-19 Associated Acute Respiratory Distress Syndrome*. https://doi.org/10.2139/ssrn.3756865

Le Bon, O., Neu, D., Berquin, Y., Lanquart, J.-P., Hoffmann, R., Mairesse, O., & Armitage, R. (2012). Ultra-slow delta power in chronic fatigue syndrome. *Psychiatry Research*, *200*(2–3), 742–747. https://doi.org/10.1016/j.psychres.2012.06.027

Lee, I.-S., Bardwell, W. A., Ancoli-Israel, S., & Dimsdale, J. E. (2010). Number of lapses during the psychomotor vigilance task as an objective measure of fatigue. *Journal of Clinical Sleep Medicine*, *6*(2), 163–168. https://doi.org/10.5664/jcsm.27766

Lejko, N., Larabi, D. I., Herrmann, C. S., Aleman, A., & Ćurčić-Blake, B. (2020). Alpha power and functional connectivity in cognitive decline: A systematic review and meta-analysis. *Journal of Alzheimer's Disease*, *78*(3), 1047–1088. https://doi.org/10.3233/JAD-200962

Lezak, M. D. (2004). *Neuropsychological assessment*. Oxford University Press, USA.

Li, G., Huang, S., Xu, W., Jiao, W., Jiang, Y., Gao, Z., & Zhang, J. (2020). The impact of mental fatigue on brain activity: A comparative study both in resting state and task state using EEG. *BMC Neuroscience*, *21*, 1–9. https://doi.org/10.1186/s12868-020-00569-1

Li, W., Yue, L., & Xiao, S. (2022). Subjective cognitive decline is associated with a higher risk of objective cognitive decline: A cross-sectional and longitudinal study. *Frontiers in Psychiatry*, *13*, 950270. https://doi.org/10.3389/fpsyt.2022.950270

Liddell, B. J., Paul, R. H., Arns, M., Gordon, N., Kukla, M., Rowe, D., Cooper, N., Moyle, J., & Williams, L. M. (2007). RATES OF DECLINE DISTINGUISH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT RELATIVE TO NORMAL AGING: INTEGRATING COGNITION AND BRAIN FUNCTION. *Journal of Integrative Neuroscience*, *06*(01), 141–174. https://doi.org/10.1142/S0219635207001374

Liu, H., Wang, J., Xin, X., Wang, P., Jiang, W., & Meng, T. (2024). The relationship and pathways between resting-state EEG, physical function, and cognitive function in older adults. *BMC Geriatrics*, *24*(1), 463. https://doi.org/10.1186/s12877-024-05041-x

Lynch, S., Ferrando, S. J., Dornbush, R., Shahar, S., Smiley, A., & Klepacz, L. (2022). Screening for brain fog: Is the montreal cognitive assessment an effective screening tool for neurocognitive complaints post-COVID-19? *General Hospital Psychiatry*, *78*, 80–86. https://doi.org/10.1016/j.genhosppsych.2022.07.013

Mantini, D., Perrucci, M. G., Del Gratta, C., Romani, G. L., & Corbetta, M. (2007). Electrophysiological signatures of resting state networks in the human brain. *Proceedings of the National Academy of Sciences*, *104*(32), 13170–13175. https://doi.org/10.1073/pnas.0700668104

Manzar, M. D., BaHammam, A. S., Hameed, U. A., Spence, D. W., Pandi-Perumal, S. R., Moscovitch, A., & Streiner, D. L. (2018). Dimensionality of the Pittsburgh Sleep Quality Index: A systematic review. *Health and Quality of Life Outcomes*, *16*, 1–22. https://doi.org/10.1186/s12955-018-0915-x

Manzar, M. D., Zannat, W., Moiz, J. A., Spence, D. W., Pandi-Perumal, S. R., Bahammam, A. S., & Hussain, M. E. (2016). Factor scoring models of the Pittsburgh sleep quality index: A

comparative confirmatory factor analysis. *Biological Rhythm Research*, *47*(6), 851–864. https://doi.org/10.1080/09291016.2016.1202375

Mattioli, F., Stampatori, C., Righetti, F., Sala, E., Tomasi, C., & De Palma, G. (2021). Neurological and cognitive sequelae of Covid-19: A four month follow-up. *Journal of Neurology*, *268*(12), 4422–4428. https://doi.org/10.1007/s00415-021-10579-6

Mazza, M. G., Palladini, M., De Lorenzo, R., Magnaghi, C., Poletti, S., Furlan, R., Ciceri, F., Rovere-Querini, P., Benedetti, F., group, C.-19 B. O. C. S., & others. (2021). Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. *Brain, Behavior, and Immunity*, *94*, 138–147. https://doi.org/10.1016/j.bbi.2021.02.021

Meghdadi, A. H., Stevanović Karić, M., McConnell, M., Rupp, G., Richard, C., Hamilton, J., Salat, D., & Berka, C. (2021). Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment. *PloS One*, *16*(2), e0244180. https://doi.org/10.1371/journal.pone.0244180

Miskowiak, K. W., Johnsen, S., Sattler, S. M., Nielsen, S., Kunalan, K., Rungby, J., Lapperre, T., & Porsberg, C. (2021). Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. *European Neuropsychopharmacology*, *46*, 39–48. https://doi.org/10.1016/j.euroneuro.2021.03.019

Mitrushina, M., Boone, K. B., Razani, J., & D'Elia, L. F. (2005). *Handbook of normative data for neuropsychological assessment*. Oxford University Press.

Molina, E., Sanabria, D., Jung, T.-P., & Correa, Á. (2019). Electroencephalographic and peripheral temperature dynamics during a prolonged psychomotor vigilance task. *Accident Analysis & Prevention*, *126*, 198–208. https://doi.org/10.1016/j.aap.2017.10.014

Mollayeva, T., Thurairajah, P., Burton, K., Mollayeva, S., Shapiro, C. M., & Colantonio, A. (2016). The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-

clinical samples: A systematic review and meta-analysis. *Sleep Medicine Reviews*, *25*, 52–73. https://doi.org/10.1016/j.smrv.2015.01.009

Montan, I., Löwe, B., Cella, D., Mehnert, A., & Hinz, A. (2018). General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale. *Value in Health*, *21*(11), 1313–1321. https://doi.org/10.1016/j.jval.2018.03.013

Moretti, D. V., Zanetti, O., Binetti, G., & Frisoni, G. B. (2012). Quantitative EEG Markers in Mild Cognitive Impairment: Degenerative versus Vascular Brain Impairment. *International Journal of Alzheimer's Disease*, *2012*, 1–12. https://doi.org/10.1155/2012/917537

Morin, L., Savale, L., Pham, T., Colle, R., Figueiredo, S., Harrois, A., Gasnier, M., Lecoq, A.-L., Meyrignac, O., Noel, N., & others. (2021). Four-month clinical status of a cohort of patients after hospitalization for COVID-19. *Jama*, *325*(15), 1525–1534. https://doi.org/10.1001/jama.2021.3331

Musaeus, C. S., Engedal, K., Høgh, P., Jelic, V., Mørup, M., Naik, M., Oeksengaard, A.-R., Snaedal, J., Wahlund, L.-O., Waldemar, G., & others. (2018). EEG theta power is an early marker of cognitive decline in dementia due to Alzheimer's disease. *Journal of Alzheimer's Disease*, *64*(4), 1359–1371. https://doi.org/10.3233/JAD-180300

Najjar, S., Najjar, A., Chong, D. J., Pramanik, B. K., Kirsch, C., Kuzniecky, R. I., Pacia, S. V., & Azhar, S. (2020). Central nervous system complications associated with SARS-CoV-2 infection: Integrative concepts of pathophysiology and case reports. *Journal of Neuroinflammation*, *17*, 1–14. https://doi.org/10.1186/s12974-020-01896-0

Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*, *53*(4), 695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x

Neo, W. S., Foti, D., Keehn, B., & Kelleher, B. (2023). Resting-state EEG power differences in autism spectrum disorder: A systematic review and meta-analysis. *Translational Psychiatry*, *13*(1), 389. https://doi.org/10.1038/s41398-023-02681-2

Newson, J. J., & Thiagarajan, T. C. (2019). EEG frequency bands in psychiatric disorders: A review of resting state studies. *Frontiers in Human Neuroscience*, *12*, 521. https://doi.org/10.3389/fnhum.2018.00521

Numbers, K., Lam, B. C., Crawford, J. D., Kochan, N. A., Sachdev, P. S., & Brodaty, H. (2023). Longitudinal changes in participant and informant reports of subjective cognitive complaints are associated with dementia risk. *Frontiers in Aging Neuroscience*, *15*, 1044807. https://doi.org/10.3389/fnagi.2023.1044807

Nunez, P. L., Silberstein, R. B., Shi, Z., Carpenter, M. R., Srinivasan, R., Tucker, D. M., Doran, S. M., Cadusch, P. J., & Wijesinghe, R. S. (1999). EEG coherency II: experimental comparisons of multiple measures. *Clinical Neurophysiology*, *110*(3), 469–486. https://doi.org/10.1016/S1388-2457(98)00043-1

Ortelli, P., Quercia, A., Cerasa, A., Dezi, S., Ferrazzoli, D., Sebastianelli, L., Saltuari, L., Versace, V., & Quartarone, A. (2023). Lowered Delta Activity in Post-COVID-19 Patients with Fatigue and Cognitive Impairment. *Biomedicines*, *11*(8), 2228. https://doi.org/10.3390/biomedicines11082228

Özbek, Y., Fide, E., & Yener, G. G. (2021). Resting-state EEG alpha/theta power ratio discriminates early-onset Alzheimer's disease from healthy controls. *Clinical Neurophysiology*, *132*(9), 2019–2031. https://doi.org/10.1016/j.clinph.2021.05.012

Pais, R., Ruano, L., P. Carvalho, O., & Barros, H. (2020). Global cognitive impairment prevalence and incidence in community dwelling older adults—A systematic review. *Geriatrics*, *5*(4), 84. https://doi.org/10.3390/geriatrics5040084

Pasini, E., Bisulli, F., Volpi, L., Minardi, I., Tappatà, M., Muccioli, L., Pensato, U., Riguzzi, P., Tinuper, P., & Michelucci, R. (2020). EEG findings in COVID-19 related encephalopathy. *Clinical Neurophysiology*, *131*(9), 2265–2267. https://doi.org/10.1016/j.clinph.2020.07.003

Pastor, J., Vega-Zelaya, L., & Martín Abad, E. (2020). Specific EEG Encephalopathy Pattern in SARS-CoV-2 Patients. *Journal of Clinical Medicine*, *9*(5), 1545. https://doi.org/10.3390/jcm9051545

Pelegrina, S., Lechuga, M. T., García-Madruga, J. A., Elosúa, M. R., Macizo, P., Carreiras, M., Fuentes, L. J., & Bajo, M. T. (2015). Normative data on the n-back task for children and young adolescents. *Frontiers in Psychology*, *6*. https://doi.org/10.3389/fpsyg.2015.01544

Perez, V., Duque, A., Hidalgo, V., & Salvador, A. (2024). EEG Frequency Bands in Subjective Cognitive Decline: A Systematic Review of Resting State Studies. *Biological Psychology*, 108823. https://doi.org/10.1016/j.biopsycho.2024.108823

Petersen, R. C. (2016). Mild cognitive impairment. *CONTINUUM: Lifelong Learning in Neurology*, *22*(2), 404–418. https://doi.org/10.1212/CON.0000000000000313

Pilotto, A., Cristillo, V., Cotti Piccinelli, S., Zoppi, N., Bonzi, G., Sattin, D., Schiavolin, S., Raggi, A., Canale, A., Gipponi, S., & others. (2021). Long-term neurological manifestations of COVID-19: Prevalence and predictive factors. *Neurological Sciences*, *42*, 4903–4907. https://doi.org/10.1007/s10072-021-05586-4

Piper, B. F., & Cella, D. (2010). Cancer-related fatigue: Definitions and clinical subtypes. *Journal of the National Comprehensive Cancer Network*, *8*(8), 958–966. https://doi.org/10.6004/jnccn.2010.0070

Posit team. (2024). *RStudio: Integrated Development Environment for R*. Posit Software, PBC. http://www.posit.co/

Premraj, L., Kannapadi, N. V., Briggs, J., Seal, S. M., Battaglini, D., Fanning, J., Suen, J., Robba, C., Fraser, J., & Cho, S.-M. (2022). Mid and long-term neurological and neuropsychiatric

manifestations of post-COVID-19 syndrome: A meta-analysis. *Journal of the Neurological Sciences*, *434*, 120162. https://doi.org/10.1016/j.jns.2022.120162

Rahimi, F., Saadat, M., Hessam, M., Ravanbakhsh, M., & Monjezi, S. (2024). Post-COVID-19 physical and cognitive impairments and associations with quality of life: A cross-sectional study. *Frontiers in Sports and Active Living*, *6*, 1246585. https://doi.org/10.3389/fspor.2024.1246585

Rass, V., Beer, R., Schiefecker, A. J., Kofler, M., Lindner, A., Mahlknecht, P., Heim, B., Limmert, V., Sahanic, S., Pizzini, A., & others. (2021). Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study. *European Journal of Neurology*, *28*(10), 3348–3359. https://doi.org/10.1111/ene.14803

Reitan, R. M., & Wolfson, D. (1985). *The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation* (Vol. 4). Neuropsychology press.

Rivas-Fernández, M. Á., Lindín, M., Zurrón, M., Díaz, F., Lojo-Seoane, C., Pereiro, A. X., & Galdo-Álvarez, S. (2023). Neuroanatomical and neurocognitive changes associated with subjective cognitive decline. *Frontiers in Medicine*, *10*, 1094799. https://doi.org/10.3389/fmed.2023.1094799

Roberto, K. T., Espiritu, A. I., Fernandez, M. L. L., & Gutierrez, J. C. (2020). Electroencephalographic findings in COVID-19 patients: A systematic review. *Seizure*, *82*, 17–22. https://doi.org/10.1016/j.seizure.2020.09.007

Rossini, P. M., Rossi, S., Babiloni, C., & Polich, J. (2007). Clinical neurophysiology of aging brain: From normal aging to neurodegeneration. *Progress in Neurobiology*, *83*(6), 375–400. http://dx.doi.org/10.1016/j.pneurobio.2007.07.010

Sánchez-Cubillo, I., Periáñez, J. A., Adrover-Roig, D., Rodríguez-Sánchez, J. M., Ríos-Lago, M., Tirapu, J., & Barceló, F. (2009). Construct validity of the Trail Making Test: Role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. *Journal*

of the International Neuropsychological Society, *15*(3), 438–450. https://doi.org/10.1017/S1355617709090626

Schild, A.-K., Goereci, Y., Scharfenberg, D., Klein, K., Lülling, J., Meiberth, D., Schweitzer, F., Stürmer, S., Zeyen, P., Sahin, D., & others. (2023). Multidomain cognitive impairment in non-hospitalized patients with the post-COVID-19 syndrome: Results from a prospective monocentric cohort. *Journal of Neurology*, *270*(3), 1215–1223. https://doi.org/10.1007/s00415-022-11444-w

Schild, A.-K., Scharfenberg, D., Kirchner, L., Klein, K., Regorius, A., Goereci, Y., Meiberth, D., Sannemann, L., Lülling, J., Schweitzer, F., & others. (2023). Subjective and objective cognitive deficits in patients with post-COVID syndrome. *Zeitschrift Für Neuropsychologie*. https://doi.org/10.1024/1016-264X/a000374

Schons, M., Pilgram, L., Reese, J.-P., Stecher, M., Anton, G., Appel, K. S., Bahmer, T., Bartschke, A., Bellinghausen, C., Bernemann, I., & others. (2022). The German National Pandemic Cohort Network (NAPKON): Rationale, study design and baseline characteristics. *European Journal of Epidemiology*, *37*(8), 849–870. https://doi.org/10.1007/s10654-022-00896-z

Schreiter-Gasser, U., Gasser, T., & Ziegler, P. (1994). Quantitative EEG analysis in early onset Alzheimer's disease: Correlations with severity, clinical characteristics, visual EEG and CCT. *Electroencephalography and Clinical Neurophysiology*, *90*(4), 267–272. https://doi.org/10.1016/0013-4694(94)90144-9

Sibilano, E., Brunetti, A., Buongiorno, D., Lassi, M., Grippo, A., Bessi, V., Micera, S., Mazzoni, A., & Bevilacqua, V. (2023). An attention-based deep learning approach for the classification of subjective cognitive decline and mild cognitive impairment using resting-state EEG. *Journal of Neural Engineering*, *20*(1), 016048. https://doi.org/10.1088/1741-2552/acb96e

Singh, K. K., Chaubey, G., Chen, J. Y., & Suravajhala, P. (2020). Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. *American Journal of Physiology-Cell Physiology*. https://doi.org/10.1152/ajpcell.00224.2020

Spinhoven, P., Ormel, J., Sloekers, P., Kempen, G., Speckens, A. E., & van Hemert, A. M. (1997). A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. *Psychological Medicine*, *27*(2), 363–370. https://doi.org/10.1017/S0033291796004382

Straus, E., Sherman, E., & Spreen, O. (2006). A compendium of neuropsychological tests: Administration, norms, and commentary. *American Journal of Hypnosis*, 267–270.

Tinsley, A., Macklin, E., Korzenik, J., & Sands, B. (2011). Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) in patients with inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, *34*(11–12), 1328–1336. https://doi.org/10.1111/j.1365-2036.2011.04871.x

Tombaugh, T. (2004). Trail Making Test A and B: Normative data stratified by age and education. *Archives of Clinical Neuropsychology*, *19*(2), 203–214. https://doi.org/10.1016/S0887-6177(03)00039-8

Tomescu, M., Rihs, T., Rochas, V., Hardmeier, M., Britz, J., Allali, G., Fuhr, P., Eliez, S., & Michel, C. (2018). From swing to cane: Sex differences of EEG resting-state temporal patterns during maturation and aging. *Developmental Cognitive Neuroscience*, *31*, 58–66. https://doi.org/10.1016/j.dcn.2018.04.011

Wang, H., Mou, S., Pei, X., Zhang, X., Shen, S., Zhang, J., Shen, X., & Shen, Z. (2025). The power spectrum and functional connectivity characteristics of resting-state EEG in patients with generalized anxiety disorder. *Scientific Reports*, *15*(1), 5991. https://doi.org/10.1038/s41598-025-90362-z

Widmann, C. N., Kolano, J., & Peper, M. (2023). Improving neuropsychological rehabilitation for COVID-19 patients. *Zeitschrift Für Neuropsychologie*. https://doi.org/10.1024/1016-264X/a000373

Wojcik, G. M., Shriki, O., Kwasniewicz, L., Kawiak, A., Ben-Horin, Y., Furman, S., Wróbel, K., Bartosik, B., & Panas, E. (2023). Investigating brain cortical activity in patients with post-

COVID-19 brain fog. *Frontiers in Neuroscience*, *17*, 1019778. https://doi.org/10.3389/fnins.2023.1019778

Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. *Journal of Pain and Symptom Management*, *13*(2), 63–74. https://doi.org/10.1016/S0885-3924(96)00274-6

Yener, G., Güntekin, B., & Başar, E. (2008). Event-related delta oscillatory responses of Alzheimer patients. *European Journal of Neurology*, *15*(6), 540–547. https://doi.org/10.1111/j.1468-1331.2008.02100.x

Zamarian, L., Rass, V., Goettfried, E., Mayr, V., Carbone, F., Kindl, P., Delazer, M., Djamshidian, A., Fanciulli, A., Mahlknecht, P., & others. (2024). Objective and subjective cognitive outcomes one year after COVID-19. *Annals of Clinical and Translational Neurology*. https://doi.org/10.1002/acn3.52149

Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. *Acta Psychiatrica Scandinavica*, *67*(6), 361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x

Appendix A

Questionnaire on demographic data and psychological and neurological conditions

Created by Christian Neumann

_____
Datum

_____
Code

Persönliche Daten:

Geburtsdatum: _____

Geschlecht: Männlich ☐   Weiblich ☐   Divers ☐   Keine Angabe ☐

Sehfähigkeit: Mit Brille Korrigiert ☐   Mit   Kontaktlinsen   korrigiert   ☐

   normal ☐

Höchster Abschluss:

Hauptschule ☐   Realschule ☐   Abitur ☐

Lehre ☐   Fachwirt ☐   Universitätsabschluss ☐

Bildungsjahre:

__ Jahre Grundschule

__ Jahre weiterführende Schule (Hauptschule/Realschule/Gymnasium

__ Jahre Ausbildung/Lehre

__ Jahre Studium

__ Gesamt

Leiden Sie an neurologischen Vorerkrankungen?

ja ☐   nein ☐

Wenn ja, welche neurologischen Vorerkrankungen?

_____

_____

_____

_____

_____

Leiden Sie an anderen sonstigen Vorerkrankungen?

_____

_____

_____

_____

_____

Appendix B

Additional Tables

Table B- 1

Defined age groups for the variables PVT, TMT-A and TMT-B

Age group	n	PVT	TMT-A	TMT-B
18 – 34 years	12	.317 ± .053	18.2 ± 3.9	39.9 ± 11.8
35 – 49 years	19	.325 ± .058	24.5 ± 7.1	45.9 ± 10.5
50 – 64 years	33	.328 ± .543	27.1 ± 7.5	59.0 ± 16.2
65 – 80 years	6	.334 ± .018	34.6 ± 10	65.1 ± 21.3

Note. PVT: Psychomotor Vigilance Task, TMT: Trail Making Test

Values denote mean ± standard deviation

Table B- 2

Two-Cluster Solution: Clusterinformation based on the self-reported group

	Cluster 1		Cluster 2	
	No reported CD	Reported CD	No reported CD	Reported CD
Socio-demographic variable				
n	8	33	19	10
Sex [F/M]	6/2	21/12	7/12	7/3
Age [years]	49.1 ± 20.0	50.9 ± 13.6	46 ± 12.8	51.5 ± 10.4
Education [years]	14.6 ± 3.7	15.0 ± 2.6	16.1 ± 3.4	51.5 ± 10.4
Cognitive variable				
PVT [s]	.362 ± .05	.362 ± .07	.288 ± .3	.293 ± .02
TMT-A [s]	28.2 ± 8.5	30.4 ± 7.9	19.0 ± 4.5	20.4 ± 2.9
TMT-B [s]	58.7 ± 24.4	63.7 ± 25.7	43.1 ± 11.1	42.7 ± 9.7
TMT-diff [s]	30.6 ± 21.1	33.3 ± 22.6	24.0 ± 10.2	22.4 ± 8.4
1-back [miss]	8.8 ± 4.1	11.9 ± 5.3	4.2 ± 3.0	9.0 ± 3.5
2-back [miss]	15.8 ± 3.1	15.6 ± 3.0	10.1 ± 4.0	11.2 ± 3.9
MoCA < 26	0	9	1	1
Questionnaires				
FACIT-F[a]	40 ± 12.1	31.4 ± 12.1	42.2 ± 8.1	**27.7 ± 11.1**
HADS-Anxiety[b]	5.9 ± 4.6	6.8 ± 3.6	3.68 ± 3.0	**8.0 ± 3.3**
HADS-Depression[b]	4.0 ± 4.7	6.1 ± 4.6	3.3 ± 4.5	6.3 ± 3.3
PSQI[c]	**6.4 ± 3.5**	**8.2 ± 4.4**	4.5 ± 2.6	**8.9 ± 3.5**

Note. PVT: Psychomotor Vigilance Task, TMT: Trail Making Test, MoCA: Montreal Cognitive Assessment, FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue Scale, HADS: Hospital Anxiety and Depression Scale, PSQI: Pittsburgh Sleep Quality Index

Values denote mean ± standard deviation

[a] scores < 31 indicate clinically significant fatigue

[b] scores > 7 indicate caseness

[c] scores > 5 indicate poor sleep quality

Table B- 3

Two-Cluster Solution: Comparison of the four subgroups in several variables

| | Kruskal-Wallis Test | | | Dunn's Test | |
	Test Statistic χ^2	d.f.	Sig.	Pairwise Comparisons	Adj. Sig.
Age	2.32	3	.0508	-	
Education	1.59	3	.662	-	
PVT	30.0	3	>.000 ***	CD C1 – No CD C1 CD C1 – CD C2 CD C1 – No CD C2 No CD C1 – No CD C2 No CD C1 – CD C2 No CD C2 – CD C2	 .003 ** >.000 *** .030 *
TMT-A	33.3	3	>.000 ***	CD C1 – No CD C1 CD C1 – CD C2 CD C1 – No CD C2 No CD C1 – No CD C2 No CD C1 – CD C2 No CD C2 – CD C2	 .002 ** >.000 *** .024 *
TMT-B	17.0	3	.001 **	CD C1 – No CD C1 CD C1 – CD C2 CD C1 – No CD C2 No CD C1 – No CD C2 No CD C1 – CD C2 No CD C2 – CD C2	 .030 * .002 **
FACIT-F	14.3	3	.003 *	CD C1 – No CD C1 CD C1 – CD C2 CD C1 – No CD C2 No CD C1 – No CD C2 No CD C1 – CD C2 No CD C2 – CD C2	 .014 * .012 *
HADS-A	12.0	3	.007 **	CD C1 – No CD C1 CD C1 – CD C2 CD C1 – No CD C2 No CD C1 – No CD C2 No CD C1 – CD C2 No CD C2 – CD C2	 .020 * .016 *
HADS-D	8.5	3	.038 *	CD C1 – No CD C1 CD C1 – CD C2 CD C1 – No CD C2 No CD C1 – No CD C2 No CD C1 – CD C2 No CD C2 – CD C2	
PSQI	11.6	3	.009 **	CD C1 – No CD C1 CD C1 – CD C2 CD C1 – No CD C2 No CD C1 – No CD C2 No CD C1 – CD C2 No CD C2 – CD C2	 .020 * .021*

Note. *p < .05, **p < .01,***p < .001. Only significant adj. p-values are displayed
Significance values for Dunn's test were adjusted by the Bonferroni correction for multiple tests
Dunn's test was performed only if the Kruskal-Wallis test yielded a significant p-value
PVT: Psychomotor Vigilance Task, TMT: Trail Making Test, FACIT-F: Functional Assessment of Chronic Illness
Therapy – Fatigue Scale, HADS: Hospital Anxiety and Depression Scale, PSQI: Pittsburgh Sleep Quality Index

Table B- 4

Four-Cluster Solution: *Comparison of the Clusters in several variables*

	Kruskal-Wallis Test			Dunn's Test	
	Test Statistic χ^2	d.f.	Sig.	Pairwise Comparisons	Adj. Sig.
Age	2.6	3	.458	-	
Education	1.6	3	.658	-	
PVT	47.0	3	>.000 ***	C1 – C2	>.000 ***
				C1 – C3	.006 **
				C1 – C4	
				C2 – C3	
				C2 – C4	>.000***
				C3 – C4	.001 **
TMT-A	38.8	3	>.000 ***	C1 – C2	.009 **
				C1 – C3	
				C1 – C4	
				C2 – C3	>.000 ***
				C2 – C4	>.000 ***
				C3 – C4	
TMT-B	34.9	3	>.0001 ***	C1 – C2	
				C1 – C3	.008 **
				C1 – C4	>.000 ***
				C2 – C3	>.000 ***
				C2 – C4	>.000 ***
				C3 – C4	
FACIT-F	3.7	3	.291	-	
HADS-A	3.3	3	.351	-	
HADS-D	2.0	3	.578	-	
PSQI	3.1	3	.376	-	

Note. *p < .05, **p < .01,***p < .001. Only significant adj. p-values are displayed

Significance values for Dunn's test were adjusted by the Bonferroni correction for multiple tests

Dunn's test was performed only if the Kruskal-Wallis test yielded a significant p-value

PVT: Psychomotor Vigilance Task, TMT: Trail Making Test, FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue Scale, HADS: Hospital Anxiety and Depression Scale, PSQI: Pittsburgh Sleep Quality Index

Appendix C

Additional Figures

Figure C- 1. The Cluster Dendrogram for the Two-Cluster Solution.

Cluster 1 = blue, Cluster 2 = orange

Figure C- 2. The Cluster Dendrogram for the Four-Cluster Solution.
Cluster 1 = pink, Cluster 2 = orange, Cluster 3 = purple, Cluster 4 = green

Appendix D

Eigenständigkeitserklärung

Ich bestätige, dass ich die vorliegende Arbeit selbstständig verfasst und keine anderen als die angegebenen Hilfsmittel verwendet habe. Die vorliegende Masterarbeit habe ich nicht bereits in derselben oder einer ähnlichen Fassung an einer anderen Fakultät oder in einem anderen Fachbereich zur Erlangung eines akademischen Grades eingereicht.

Mit der Einstellung dieser Arbeit in die Institutsbibliothek des Institutes für Psychologie bin ich einverstanden.

Kopenhagen, 31.03.2025
_____   _____
Ort, Datum   Unterschrift